{
  "$schema": "folio-library-document/v1",
  "id": "10665-44759",
  "title": "Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries : policy statement",
  "variant": "pdf",
  "pages": 70,
  "tocSource": "inferred",
  "tocMethod": "contents",
  "toc": [
    {
      "level": 1,
      "title": "Background",
      "number": "1",
      "page": 9,
      "pageLabel": "1",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-000-1-background"
    },
    {
      "level": 1,
      "title": "Methods",
      "number": "2",
      "page": 11,
      "pageLabel": "3",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-001-2-methods"
    },
    {
      "level": 2,
      "title": "Evidence synthesis",
      "number": "2.1",
      "page": 11,
      "pageLabel": "3",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-002-21-evidence-synthesis"
    },
    {
      "level": 2,
      "title": "Decision-making during the Expert Group meeting and external review",
      "number": "2.2",
      "page": 13,
      "pageLabel": "5",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-003-22-decision-making-during-the-expert-group-meeti"
    },
    {
      "level": 2,
      "title": "Scope of the policy guidance",
      "number": "2.3",
      "page": 14,
      "pageLabel": "6",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-004-23-scope-of-the-policy-guidance"
    },
    {
      "level": 1,
      "title": "Evidence base for policy formulation",
      "number": "3",
      "page": 15,
      "pageLabel": "7",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-005-3-evidence-base-for-policy-formulation"
    },
    {
      "level": 2,
      "title": "Use of IGRAs in diagnosis of active TB",
      "number": "3.1",
      "page": 15,
      "pageLabel": "7",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-006-31-use-of-igras-in-diagnosis-of-active-tb"
    },
    {
      "level": 3,
      "title": "Study characteristics",
      "number": "3.1.1",
      "page": 15,
      "pageLabel": "7",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-007-311-study-characteristics"
    },
    {
      "level": 3,
      "title": "Summary of results",
      "number": "3.1.2",
      "page": 15,
      "pageLabel": "7",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-008-312-summary-of-results"
    },
    {
      "level": 3,
      "title": "Strengths and limitations of the evidence base",
      "number": "3.1.3",
      "page": 16,
      "pageLabel": "8",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-009-313-strengths-and-limitations-of-the-evidence-ba"
    },
    {
      "level": 3,
      "title": "Grade evidence profiles and final policy recommendations",
      "number": "3.1.4",
      "page": 17,
      "pageLabel": "9",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-010-314-grade-evidence-profiles-and-final-policy-rec"
    },
    {
      "level": 2,
      "title": "Use of IGRAs in children",
      "number": "3.2",
      "page": 18,
      "pageLabel": "10",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-011-32-use-of-igras-in-children"
    },
    {
      "level": 3,
      "title": "Study characteristics",
      "number": "3.2.1",
      "page": 18,
      "pageLabel": "10",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-012-321-study-characteristics"
    },
    {
      "level": 3,
      "title": "Summary of results",
      "number": "3.2.2",
      "page": 18,
      "pageLabel": "10",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-013-322-summary-of-results"
    },
    {
      "level": 3,
      "title": "Strengths and limitations of the evidence base",
      "number": "3.2.3",
      "page": 19,
      "pageLabel": "11",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-014-323-strengths-and-limitations-of-the-evidence-ba"
    },
    {
      "level": 3,
      "title": "Grade evidence profiles and final policy recommendations",
      "number": "3.2.4",
      "page": 20,
      "pageLabel": "12",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-015-324-grade-evidence-profiles-and-final-policy-rec"
    },
    {
      "level": 2,
      "title": "Use of IGRAs for the diagnosis of LTBI in HIV-infected individuals",
      "number": "3.3",
      "page": 21,
      "pageLabel": "13",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-016-33-use-of-igras-for-the-diagnosis-of-ltbi-in-hiv"
    },
    {
      "level": 3,
      "title": "Study characteristics",
      "number": "3.3.1",
      "page": 21,
      "pageLabel": "13",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-017-331-study-characteristics"
    },
    {
      "level": 3,
      "title": "Summary of results",
      "number": "3.3.2",
      "page": 21,
      "pageLabel": "13",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-018-332-summary-of-results"
    },
    {
      "level": 3,
      "title": "Strengths and limitations of the evidence base",
      "number": "3.3.3",
      "page": 22,
      "pageLabel": "14",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-019-333-strengths-and-limitations-of-the-evidence-ba"
    },
    {
      "level": 3,
      "title": "Grade evidence profiles and final policy recommendations",
      "number": "3.3.4",
      "page": 22,
      "pageLabel": "14",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-020-334-grade-evidence-profiles-and-final-policy-rec"
    },
    {
      "level": 2,
      "title": "Use of IGRAs for screening of health care workers",
      "number": "3.4",
      "page": 23,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-021-34-use-of-igras-for-screening-of-health-care-wor"
    },
    {
      "level": 3,
      "title": "Study characteristics",
      "number": "3.4.1",
      "page": 23,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-022-341-study-characteristics"
    },
    {
      "level": 3,
      "title": "Summary of results",
      "number": "3.4.2",
      "page": 23,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-023-342-summary-of-results"
    },
    {
      "level": 3,
      "title": "Strengths and limitations of the evidence base",
      "number": "3.4.3",
      "page": 23,
      "pageLabel": "15",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-024-343-strengths-and-limitations-of-the-evidence-ba"
    },
    {
      "level": 3,
      "title": "Grade evidence profiles and final policy recommendations",
      "number": "3.4.4",
      "page": 24,
      "pageLabel": "16",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-025-344-grade-evidence-profiles-and-final-policy-rec"
    },
    {
      "level": 2,
      "title": "Use of IGRAs in contact screening and outbreak investigations",
      "number": "3.5",
      "page": 25,
      "pageLabel": "17",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-026-35-use-of-igras-in-contact-screening-and-outbrea"
    },
    {
      "level": 3,
      "title": "Study characteristics",
      "number": "3.5.1",
      "page": 25,
      "pageLabel": "17",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-027-351-study-characteristics"
    },
    {
      "level": 3,
      "title": "Summary of results",
      "number": "3.5.2",
      "page": 25,
      "pageLabel": "17",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-028-352-summary-of-results"
    },
    {
      "level": 3,
      "title": "Strengths and limitations of the evidence base",
      "number": "3.5.3",
      "page": 26,
      "pageLabel": "18",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-029-353-strengths-and-limitations-of-the-evidence-ba"
    },
    {
      "level": 3,
      "title": "Grade evidence profiles and final policy recommendations",
      "number": "3.5.4",
      "page": 26,
      "pageLabel": "18",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-030-354-grade-evidence-profiles-and-final-policy-rec"
    },
    {
      "level": 2,
      "title": "The predictive value of IGRAs for incident active TB",
      "number": "3.6",
      "page": 27,
      "pageLabel": "19",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-031-36-the-predictive-value-of-igras-for-incident-ac"
    },
    {
      "level": 3,
      "title": "Study characteristics",
      "number": "3.6.1",
      "page": 27,
      "pageLabel": "19",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-032-361-study-characteristics"
    },
    {
      "level": 3,
      "title": "Summary of results",
      "number": "3.6.2",
      "page": 27,
      "pageLabel": "19",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-033-362-summary-of-results"
    },
    {
      "level": 3,
      "title": "Grade evidence profiles and final policy recommendations",
      "number": "3.6.3",
      "page": 27,
      "pageLabel": "19",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-034-363-grade-evidence-profiles-and-final-policy-rec"
    },
    {
      "level": 1,
      "title": "Operational aspects on the use of IGRAs",
      "number": "4",
      "page": 28,
      "pageLabel": "20",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-035-4-operational-aspects-on-the-use-of-igras"
    },
    {
      "level": 1,
      "title": "Overall conclusions",
      "number": "5",
      "page": 28,
      "pageLabel": "20",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-036-5-overall-conclusions"
    },
    {
      "level": 1,
      "title": "Implications for further research",
      "number": "6",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-037-6-implications-for-further-research"
    },
    {
      "level": 1,
      "title": "GRADE tables",
      "number": "7",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-038-7-grade-tables"
    },
    {
      "level": 1,
      "title": "Selected references",
      "number": "8",
      "page": 31,
      "pageLabel": "23",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-039-8-selected-references"
    },
    {
      "level": 1,
      "title": "List of Participants - Expert Group meeting",
      "number": "Annex 1",
      "page": 65,
      "pageLabel": "57",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-040-annex-1-list-of-participants---expert-group-meet"
    },
    {
      "level": 1,
      "title": "List of Participants - STAG-TB",
      "number": "Annex 2",
      "page": 68,
      "pageLabel": "60",
      "confidence": 0.95,
      "evidence": [
        "contents",
        "body",
        "style",
        "number"
      ],
      "source": "inferred",
      "section": "sec-041-annex-2-list-of-participants---stag-tb"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 9,
      "labelStart": null,
      "labelEnd": "1",
      "words": 3148,
      "summary": {
        "text": "The front matter of WHO's 2011 policy statement on the use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. It includes cataloguing and copyright details, the table of contents and summary material. It ends with declarations of interest, explaining that experts with IGRA research links and the systematic reviewers did not take part in the GRADE evaluation or in forming recommendations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "igras nor",
          "heading": false
        },
        {
          "term": "neither igras",
          "heading": false
        },
        {
          "term": "commercial igras",
          "heading": false
        },
        {
          "term": "expert group",
          "heading": false
        },
        {
          "term": "middle-income countries",
          "heading": false
        },
        {
          "term": "brien declared",
          "heading": false
        },
        {
          "term": "middle-income settings",
          "heading": false
        },
        {
          "term": "evidence profiles",
          "heading": false
        }
      ],
      "extract": "Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle- income countries Policy Statement 2011 WHO Library Cataloguing-in-Publication Data Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement. 1.Interferon-gamma. 2.Tuberculosis, Pulmonary - diagnosis. 3.Immunoassay - methods. 4.Reagent kits, diagnostic. 5.Developing countries.",
      "extractCut": true,
      "blocks": [
        "library/10665-44759/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-1-background",
      "number": "1",
      "title": "Background",
      "level": 1,
      "pageStart": 9,
      "pageEnd": 11,
      "labelStart": "1",
      "labelEnd": "3",
      "words": 1572,
      "summary": {
        "text": "Describes the background to the IGRA policy statement, noting that about a third of the world's population has latent TB infection and that the tuberculin skin test long was the only detection tool, with known limitations. It explains how IGRAs work and their growing commercial promotion in high-burden settings. It argues that their role needed evaluation in low- and middle-income countries with limited public health resources.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst reactivity",
          "heading": false
        },
        {
          "term": "commercial igras",
          "heading": false
        },
        {
          "term": "decreased tst",
          "heading": false
        },
        {
          "term": "tst sensitivity",
          "heading": false
        },
        {
          "term": "tuberculosis antigens",
          "heading": false
        },
        {
          "term": "bovis bcg",
          "heading": false
        },
        {
          "term": "cellular immune",
          "heading": false
        },
        {
          "term": "tuberculosis infection",
          "heading": false
        }
      ],
      "extract": "Background Tuberculosis (TB) continues to have a significant health impact worldwide, with one third of the world’s population estimated to be infected with Mycobacterium tuberculosis, resulting in so-called latent TB infection (LTBI). Until recently, the tuberculin skin test (TST) was the only tool available for LTBI detection. The TST involves intradermal injection of purified protein derivative (PPD), a crude",
      "extractCut": true
    },
    {
      "id": "sec-001-2-methods",
      "number": "2",
      "title": "Methods",
      "level": 1,
      "pageStart": 11,
      "pageEnd": 11,
      "labelStart": "3",
      "labelEnd": "3",
      "words": 1,
      "summary": {
        "text": "A section heading for the methods chapter, with no further text.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Methods",
      "extractCut": false
    },
    {
      "id": "sec-002-21-evidence-synthesis",
      "number": "2.1",
      "title": "Evidence synthesis",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 13,
      "labelStart": "3",
      "labelEnd": "5",
      "words": 1012,
      "summary": {
        "text": "Describes the evidence synthesis behind the IGRA policy, following WHO's process of systematic reviews and meta-analysis of diagnostic accuracy studies followed by an Expert Group review using the GRADE approach. It sets out how studies were selected, data extracted and quality assessed. It explains how results were pooled, or summarized when fewer than four studies were available.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence synthesis",
          "heading": true
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "igra manufacturers",
          "heading": false
        },
        {
          "term": "individual topic",
          "heading": false
        },
        {
          "term": "systematic reviews",
          "heading": false
        },
        {
          "term": "accuracy studies",
          "heading": false
        },
        {
          "term": "expert group",
          "heading": false
        },
        {
          "term": "ifn-γ response",
          "heading": false
        }
      ],
      "extract": "Evidence synthesis The systematic, structured, evidence-based process for TB diagnostic policy generation developed by WHO-STB was followed: The first step constituted systematic reviews and meta-analysis of available data (published and unpublished) using standard methods appropriate for diagnostic accuracy studies. The second step involved the convening of an Expert Group to a) evaluate the strength of the",
      "extractCut": true
    },
    {
      "id": "sec-003-22-decision-making-during-the-expert-group-meeti",
      "number": "2.2",
      "title": "Decision-making during the Expert Group meeting and external review",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 14,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 152,
      "summary": {
        "text": "Explains that the Expert Group reviewed the systematic reviews in advance and reached decisions by consensus, with members' concerns recorded in the meeting report. The final policy was approved by WHO's Guidelines Review Committee.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "expert group",
          "heading": true
        },
        {
          "term": "group meeting",
          "heading": true
        },
        {
          "term": "who-stb secretariat",
          "heading": false
        },
        {
          "term": "stag-tb",
          "heading": false
        },
        {
          "term": "group members",
          "heading": false
        }
      ],
      "extract": "Decision-making during the Expert Group meeting and external review The systematic reviews were made available to the Expert Group for scrutiny before the meeting. The Expert Group meeting was co-chaired by the WHO-STB secretariat and an evidence synthesis expert. Decisions were based on consensus. Concerns and opinions by Expert Group members were noted and included in the final meeting report. The detailed meeting",
      "extractCut": true
    },
    {
      "id": "sec-004-23-scope-of-the-policy-guidance",
      "number": "2.3",
      "title": "Scope of the policy guidance",
      "level": 2,
      "pageStart": 14,
      "pageEnd": 15,
      "labelStart": "6",
      "labelEnd": "7",
      "words": 146,
      "summary": {
        "text": "Defines the scope of the policy guidance as a pragmatic summary of evidence and recommendations on IGRAs in low- and middle-income countries, intended for national TB programme managers and to be read with the Expert Group report.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "policy guidance",
          "heading": true
        },
        {
          "term": "middle-income countries",
          "heading": false
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "scope",
          "heading": true
        },
        {
          "term": "laboratory",
          "heading": false
        }
      ],
      "extract": "Scope of the policy guidance This document provides a pragmatic summary of the evidence and recommendations related to the use of IGRAs in low- and middle-income countries and should be read in conjunction with the detailed findings from the Expert Group Meeting Report. This policy guidance should be used to inform the use of IGRAs in low- and middle-income countries. It is intended for National TB Programme",
      "extractCut": true
    },
    {
      "id": "sec-005-3-evidence-base-for-policy-formulation",
      "number": "3",
      "title": "Evidence base for policy formulation",
      "level": 1,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 5,
      "summary": {
        "text": "A section heading for the evidence base for policy formulation.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Evidence base for policy formulation",
      "extractCut": false
    },
    {
      "id": "sec-006-31-use-of-igras-in-diagnosis-of-active-tb",
      "number": "3.1",
      "title": "Use of IGRAs in diagnosis of active TB",
      "level": 2,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 8,
      "summary": {
        "text": "A section heading for the use of IGRAs in diagnosing active TB.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Use of IGRAs in diagnosis of active TB",
      "extractCut": false
    },
    {
      "id": "sec-007-311-study-characteristics",
      "number": "3.1.1",
      "title": "Study characteristics",
      "level": 3,
      "pageStart": 15,
      "pageEnd": 15,
      "labelStart": "7",
      "labelEnd": "7",
      "words": 265,
      "summary": {
        "text": "Describes the studies included on IGRAs for diagnosing active pulmonary TB in adults in low- and middle-income countries, limited to the two current commercial assays. It explains how sensitivity and specificity were estimated, the latter only among suspects found not to have active TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "quantiferon-tb gold",
          "heading": false
        },
        {
          "term": "middle-income countries",
          "heading": false
        },
        {
          "term": "suspects",
          "heading": false
        },
        {
          "term": "diagnostic accuracy",
          "heading": false
        },
        {
          "term": "active",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        },
        {
          "term": "oxford",
          "heading": false
        }
      ],
      "extract": "Study characteristics Studies included were those that evaluated the performance of the most recent generation of commercial, RD1 antigen based IGRAs (QuantiFERON-TB Gold In-Tube (QFT-GIT) [Celestis, Victoria, Australia] and T-SPOT [Oxford Immunotec, Oxford, United Kingdom]) among adult (>15 years) active pulmonary TB suspects or cases in low- and middle-income countries. Studies excluded were those that evaluated",
      "extractCut": true
    },
    {
      "id": "sec-008-312-summary-of-results",
      "number": "3.1.2",
      "title": "Summary of results",
      "level": 3,
      "pageStart": 15,
      "pageEnd": 16,
      "labelStart": "7",
      "labelEnd": "8",
      "words": 362,
      "summary": {
        "text": "Reports that IGRAs had sensitivity of 73–83% and specificity of 49–58% for active TB in low- and middle-income countries, so about one in four culture-confirmed patients could test negative. It also notes industry involvement in some of the studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "both igras",
          "heading": false
        },
        {
          "term": "hiv-positive patients",
          "heading": false
        },
        {
          "term": "active",
          "heading": false
        },
        {
          "term": "igra-negative",
          "heading": false
        },
        {
          "term": "added value",
          "heading": false
        },
        {
          "term": "extra-pulmonary",
          "heading": false
        },
        {
          "term": "t-spot",
          "heading": false
        },
        {
          "term": "demonstrated",
          "heading": false
        }
      ],
      "extract": "Summary of results The results demonstrated that in low- and middle-income countries:  The sensitivity of IGRAs in detecting active TB among persons suspected of having TB ranged from 73-83% and specificity ranged from 49-58%; One in four patients, on average, with culture- confirmed active TB could therefore be expected to be IGRA-negative in low-and middle income countries, with serious consequences for patients",
      "extractCut": true
    },
    {
      "id": "sec-009-313-strengths-and-limitations-of-the-evidence-ba",
      "number": "3.1.3",
      "title": "Strengths and limitations of the evidence base",
      "level": 3,
      "pageStart": 16,
      "pageEnd": 17,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 216,
      "summary": {
        "text": "Describes the strengths and limitations of the evidence on IGRAs for active TB, including substantial heterogeneity and the steps taken to reduce it. It also notes the lack of standard definitions of high-incidence settings and of data on patient outcomes or preferences.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "publication bias",
          "heading": false
        },
        {
          "term": "strengths",
          "heading": true
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "limitations",
          "heading": true
        },
        {
          "term": "heterogeneity",
          "heading": false
        },
        {
          "term": "incidence",
          "heading": false
        },
        {
          "term": "base",
          "heading": true
        }
      ],
      "extract": "Strengths and limitations of the evidence base Heterogeneity was substantial for the primary outcomes of sensitivity and specificity. Empirical random effects weighting, excluding studies contributing fewer than 10 eligible individuals, and separately synthesizing data for currently manufactured IGRAs were performed in order to minimize heterogeneity. No standard criteria exist for defining high TB incidence",
      "extractCut": true
    },
    {
      "id": "sec-010-314-grade-evidence-profiles-and-final-policy-rec",
      "number": "3.1.4",
      "title": "Grade evidence profiles and final policy recommendations",
      "level": 3,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "9",
      "labelEnd": "10",
      "words": 216,
      "summary": {
        "text": "Presents the Expert Group's conclusion that evidence for IGRAs and the skin test in diagnosing active TB was of low quality. It gives the strong recommendation against using them instead of microbiological diagnosis in low- and middle-income countries, given the harm of false positives.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence profiles",
          "heading": true
        },
        {
          "term": "grade evidence",
          "heading": true
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "diagnostic work-up",
          "heading": false
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "middle-income countries",
          "heading": false
        }
      ],
      "extract": "Grade evidence profiles and final policy recommendations The GRADE evidence profiles are provided in Tables 1 and 2. Based on these assessments, the Expert Group concluded that the quality of evidence for use of IGRAs and the TST in diagnosis of active TB was low and recommended that these tests should not be used in low- and middle-income countries as a replacement for conventional microbiological diagnosis of",
      "extractCut": true
    },
    {
      "id": "sec-011-32-use-of-igras-in-children",
      "number": "3.2",
      "title": "Use of IGRAs in children",
      "level": 2,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 5,
      "summary": {
        "text": "A section heading for the use of IGRAs in children.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Use of IGRAs in children",
      "extractCut": false
    },
    {
      "id": "sec-012-321-study-characteristics",
      "number": "3.2.1",
      "title": "Study characteristics",
      "level": 3,
      "pageStart": 18,
      "pageEnd": 18,
      "labelStart": "10",
      "labelEnd": "10",
      "words": 244,
      "summary": {
        "text": "Describes the studies on IGRAs in children found through the literature search, covering evaluations in 18 countries. Only a minority came from low- and middle-income countries, and definitions of TB suspects and controls varied.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "middle-income countries",
          "heading": false
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "t-spot",
          "heading": false
        },
        {
          "term": "test performance",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        },
        {
          "term": "characteristics",
          "heading": true
        },
        {
          "term": "children",
          "heading": false
        }
      ],
      "extract": "Study characteristics The initial search yielded 234 citations. After full-text review of 68 papers evaluating IGRAs in children, 32 were determined to meet eligibility criteria, covering 33 unique evaluations of one or more IGRAs (hereafter referred to as studies) in 18 countries. Of the 33 studies, three were from low-income countries, and 11 were from middle-income countries. The incidence of smear-positive TB",
      "extractCut": true
    },
    {
      "id": "sec-013-322-summary-of-results",
      "number": "3.2.2",
      "title": "Summary of results",
      "level": 3,
      "pageStart": 18,
      "pageEnd": 19,
      "labelStart": "10",
      "labelEnd": "11",
      "words": 370,
      "summary": {
        "text": "Reports that most paediatric IGRA studies came from high-income countries, and that in lower-resource settings IGRAs and the skin test showed very similar accuracy for latent and active TB in children. It notes implementation issues such as blood collection and manufacturer support for many studies, mainly through donated kits.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "both igras",
          "heading": false
        },
        {
          "term": "bcg coverage",
          "heading": false
        },
        {
          "term": "test accuracy",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "lower sensitivity",
          "heading": false
        },
        {
          "term": "children",
          "heading": false
        },
        {
          "term": "ltbi",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        }
      ],
      "extract": "Summary of results The majority of IGRA studies in children had been performed in high-income countries and extrapolation to low- and middle-income settings with high background TB infection rates was not appropriate. However, based on available data, the results indicated that in low- and middle-income countries:  IGRAs and the TST had very similar accuracy for diagnosis of LTBI and active TB in children;  Major",
      "extractCut": true
    },
    {
      "id": "sec-014-323-strengths-and-limitations-of-the-evidence-ba",
      "number": "3.2.3",
      "title": "Strengths and limitations of the evidence base",
      "level": 3,
      "pageStart": 19,
      "pageEnd": 20,
      "labelStart": "11",
      "labelEnd": "12",
      "words": 276,
      "summary": {
        "text": "Describes limitations of the paediatric evidence, including very different populations, methods and non-standard reference definitions. Sample sizes were often small, and no data were available on patient outcomes or preferences.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "publication bias",
          "heading": false
        },
        {
          "term": "strengths",
          "heading": true
        },
        {
          "term": "surrogate",
          "heading": false
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "limitations",
          "heading": true
        },
        {
          "term": "heterogeneity",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        },
        {
          "term": "base",
          "heading": true
        }
      ],
      "extract": "Strengths and limitations of the evidence base Studies included assessed very different populations in diverse settings, with the biggest challenge and limitation related to major differences in methodological approaches across studies and non- standardised definitions of reference standards, TB exposure and TB disease. Sample sizes in the different studies varied greatly and were less than ten in some of the",
      "extractCut": true
    },
    {
      "id": "sec-015-324-grade-evidence-profiles-and-final-policy-rec",
      "number": "3.2.4",
      "title": "Grade evidence profiles and final policy recommendations",
      "level": 3,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "12",
      "labelEnd": "13",
      "words": 210,
      "summary": {
        "text": "Presents the Expert Group's finding that evidence on IGRAs in children was very low quality. It recommends against using them instead of the skin test for latent or active TB in children in low- and middle-income countries, noting harms of blood collection and unaddressed cost and acceptability.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence profiles",
          "heading": true
        },
        {
          "term": "grade evidence",
          "heading": true
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "harms associated",
          "heading": false
        },
        {
          "term": "additional harms",
          "heading": false
        },
        {
          "term": "blood collection",
          "heading": false
        }
      ],
      "extract": "Grade evidence profiles and final policy recommendations The GRADE evidence profiles are provided in Tables 3 to 6. Based on these assessments, the Expert Group concluded that the quality of evidence for use of IGRAS in children was very low and recommended that these tests should not be used in low- and middle-income countries as an alternative to TST in paediatric TB for the diagnosis of latent TB infection, nor",
      "extractCut": true
    },
    {
      "id": "sec-016-33-use-of-igras-for-the-diagnosis-of-ltbi-in-hiv",
      "number": "3.3",
      "title": "Use of IGRAs for the diagnosis of LTBI in HIV-infected individuals",
      "level": 2,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "13",
      "labelEnd": "13",
      "words": 11,
      "summary": {
        "text": "A section heading for the use of IGRAs to diagnose latent TB in people living with HIV.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Use of IGRAs for the diagnosis of LTBI in HIV-infected individuals",
      "extractCut": false
    },
    {
      "id": "sec-017-331-study-characteristics",
      "number": "3.3.1",
      "title": "Study characteristics",
      "level": 3,
      "pageStart": 21,
      "pageEnd": 21,
      "labelStart": "13",
      "labelEnd": "13",
      "words": 105,
      "summary": {
        "text": "Describes the studies on IGRAs in immunocompromised people, most from low- and middle-income countries, with wide variation in design and in whether participants with HIV were symptomatic.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study",
          "heading": true
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "asymptomatic",
          "heading": false
        },
        {
          "term": "hereafter",
          "heading": false
        }
      ],
      "extract": "Study characteristics The initial search yielded 791 citations. After full-text review of 129 papers evaluating IGRAs in immunocompromised individuals, 29 were determined to meet eligibility criteria, covering 37 unique evaluations (hereafter referred to as studies). Of these, 22 studies were conducted in low- and middle-income countries. There was a high degree of variation in study design and study populations.",
      "extractCut": true
    },
    {
      "id": "sec-018-332-summary-of-results",
      "number": "3.3.2",
      "title": "Summary of results",
      "level": 3,
      "pageStart": 21,
      "pageEnd": 22,
      "labelStart": "13",
      "labelEnd": "14",
      "words": 345,
      "summary": {
        "text": "Reports that the best test for identifying people with HIV who could benefit from isoniazid preventive therapy remains unclear, and that IGRAs and the skin test performed similarly in people with HIV. It notes industry involvement in some studies.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "hiv-infected persons",
          "heading": false
        },
        {
          "term": "predictive value",
          "heading": false
        },
        {
          "term": "hiv-infected individuals",
          "heading": false
        },
        {
          "term": "ipt",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "active",
          "heading": false
        },
        {
          "term": "reduction",
          "heading": false
        }
      ],
      "extract": "Summary of results Results indicated that in low- and middle-income countries:  The optimal test for identifying HIV-infected persons who could benefit from IPT remains an unanswered question although WHO recently endorsed IPT as one of three key public health strategies to reduce the impact of TB on persons living with HIV;  The majority of persons latently infected with TB, including persons co-infected with",
      "extractCut": true
    },
    {
      "id": "sec-019-333-strengths-and-limitations-of-the-evidence-ba",
      "number": "3.3.3",
      "title": "Strengths and limitations of the evidence base",
      "level": 3,
      "pageStart": 22,
      "pageEnd": 22,
      "labelStart": "14",
      "labelEnd": "14",
      "words": 106,
      "summary": {
        "text": "Notes the main limitation of the evidence for people with HIV: no adequate reference standard for latent TB, together with small studies and few head-to-head comparisons.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "strengths",
          "heading": true
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "reference standard",
          "heading": false
        }
      ],
      "extract": "Strengths and limitations of the evidence base The major limitation was the lack of an adequate reference standard to evaluate the accuracy of IGRAs for diagnosis of LTBI. The majority of studies were small (< 100 patients in 12 of 22 studies), only five studies performed a head-to-head comparison of IGRA and TST results to a reference standard, and there were insufficient studies to perform meta-analysis in many",
      "extractCut": true
    },
    {
      "id": "sec-020-334-grade-evidence-profiles-and-final-policy-rec",
      "number": "3.3.4",
      "title": "Grade evidence profiles and final policy recommendations",
      "level": 3,
      "pageStart": 22,
      "pageEnd": 23,
      "labelStart": "14",
      "labelEnd": "15",
      "words": 122,
      "summary": {
        "text": "Presents the Expert Group's strong recommendation that IGRAs not replace the skin test for latent TB in people living with HIV in low- and middle-income countries, applying also to children with HIV.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence profiles",
          "heading": true
        },
        {
          "term": "grade evidence",
          "heading": true
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "middle-income countries",
          "heading": false
        }
      ],
      "extract": "Grade evidence profiles and final policy recommendations The GRADE evidence profiles are provided in Tables 7 and 8. Based on these assessments, the Expert Group concluded that the quality of evidence for use of IGRAS in individuals living with HIV infection was very low and recommended that these tests should not be used in low- and middle-income countries as a replacement for TST for the assessment of LTBI (strong",
      "extractCut": true
    },
    {
      "id": "sec-021-34-use-of-igras-for-screening-of-health-care-wor",
      "number": "3.4",
      "title": "Use of IGRAs for screening of health care workers",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 9,
      "summary": {
        "text": "A section heading for the use of IGRAs in screening health care workers.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Use of IGRAs for screening of health care workers",
      "extractCut": false
    },
    {
      "id": "sec-022-341-study-characteristics",
      "number": "3.4.1",
      "title": "Study characteristics",
      "level": 3,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 109,
      "summary": {
        "text": "Describes the studies on IGRAs for screening health care workers, very few of them from low- and middle-income settings, with widely varying designs and exposure risks.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "study",
          "heading": true
        },
        {
          "term": "hcws",
          "heading": false
        },
        {
          "term": "varied",
          "heading": false
        },
        {
          "term": "characteristics",
          "heading": true
        }
      ],
      "extract": "Study characteristics The initial search yielded 546 citations. After full-text review of 56 papers evaluating commercial IGRAs in health care workers (HCWs), 48 were deemed to have met the eligibility criteria. Of these, only five (12%) were done in low- and middle-income settings. Studies varied greatly in design, execution, and reported outcomes. IGRA performance varied greatly across populations; therefore,",
      "extractCut": true
    },
    {
      "id": "sec-023-342-summary-of-results",
      "number": "3.4.2",
      "title": "Summary of results",
      "level": 3,
      "pageStart": 23,
      "pageEnd": 23,
      "labelStart": "15",
      "labelEnd": "15",
      "words": 267,
      "summary": {
        "text": "Reports that latent TB prevalence among health care workers depended on the test used and the TB incidence setting, with high skin test positivity and slightly lower IGRA positivity. There was no evidence that IGRAs detected new infections better than the skin test.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst positivity",
          "heading": false
        },
        {
          "term": "reversions",
          "heading": false
        },
        {
          "term": "positivity rates",
          "heading": false
        },
        {
          "term": "conversions",
          "heading": false
        },
        {
          "term": "bcg vaccination",
          "heading": false
        },
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "serial testing",
          "heading": false
        },
        {
          "term": "hcws",
          "heading": false
        }
      ],
      "extract": "Summary of results Results indicated that in low- and middle-income countries:  Prevalence of LTBI in HCWs depended on the test used and the particular TB incidence setting. Two cross-sectional studies comparing IGRA and TST positivity rates in HCWs showed high TST positivity rates (40% to 66%) and slightly lower rate for IGRA positivity (statistically significant in only one study, which also showed the lowest",
      "extractCut": true
    },
    {
      "id": "sec-024-343-strengths-and-limitations-of-the-evidence-ba",
      "number": "3.4.3",
      "title": "Strengths and limitations of the evidence base",
      "level": 3,
      "pageStart": 23,
      "pageEnd": 24,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 61,
      "summary": {
        "text": "Describes the strengths and limitations of the review on health care worker screening, noting a broad search but only two relevant studies and very limited serial testing and predictive data.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "strengths",
          "heading": true
        },
        {
          "term": "evidence",
          "heading": true
        },
        {
          "term": "limitations",
          "heading": true
        }
      ],
      "extract": "Strengths and limitations of the evidence base The systematic review used a comprehensive search strategy using multiple sources and databases to retrieve relevant studies, including unpublished studies and conference proceedings. Only two studies in low- or middle-income countries were identified. Serial testing data, evidence on the predictive value of IGRAs in HCWs, as well as reproducibility data were seriously",
      "extractCut": true
    },
    {
      "id": "sec-025-344-grade-evidence-profiles-and-final-policy-rec",
      "number": "3.4.4",
      "title": "Grade evidence profiles and final policy recommendations",
      "level": 3,
      "pageStart": 24,
      "pageEnd": 25,
      "labelStart": "16",
      "labelEnd": "17",
      "words": 118,
      "summary": {
        "text": "Presents the strong recommendation against using IGRAs to screen health care workers in low- and middle-income countries, based on very low-quality evidence.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence profiles",
          "heading": true
        },
        {
          "term": "grade evidence",
          "heading": true
        },
        {
          "term": "worker screening",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        }
      ],
      "extract": "Grade evidence profiles and final policy recommendations The GRADE evidence profiles are provided in Tables 9 and 10. Based on these assessments, the Expert Group concluded that the quality of evidence for use of IGRAS for screening in health care workers in low- and middle-income countries was very low and recommended that these tests should not be used in health care worker screening programmes in these countries",
      "extractCut": true
    },
    {
      "id": "sec-026-35-use-of-igras-in-contact-screening-and-outbrea",
      "number": "3.5",
      "title": "Use of IGRAs in contact screening and outbreak investigations",
      "level": 2,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 9,
      "summary": {
        "text": "A section heading for the use of IGRAs in contact screening and outbreak investigations.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "Use of IGRAs in contact screening and outbreak investigations",
      "extractCut": false
    },
    {
      "id": "sec-027-351-study-characteristics",
      "number": "3.5.1",
      "title": "Study characteristics",
      "level": 3,
      "pageStart": 25,
      "pageEnd": 25,
      "labelStart": "17",
      "labelEnd": "17",
      "words": 246,
      "summary": {
        "text": "Describes the studies on IGRAs in contact screening and outbreak investigations in low- and middle-income countries after excluding high-income and in-house assay studies. Most were small and few reported blinding of test interpretation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "adult contacts",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        },
        {
          "term": "study",
          "heading": true
        },
        {
          "term": "unpublished study",
          "heading": false
        },
        {
          "term": "unreported",
          "heading": false
        },
        {
          "term": "study population",
          "heading": false
        },
        {
          "term": "infection rate",
          "heading": false
        },
        {
          "term": "studies",
          "heading": false
        }
      ],
      "extract": "Study characteristics The initial search yielded 608 citations. After full-text review of 99 papers evaluating commercial IGRAs in screening of contacts and outbreak investigations, 65 studies conducted in high-income countries were excluded, as were 18 studies using pre-commercial and in-house IGRAs. 16 studies were deemed to have met the eligibility criteria. Most studies were small (39-301 participants); however,",
      "extractCut": true
    },
    {
      "id": "sec-028-352-summary-of-results",
      "number": "3.5.2",
      "title": "Summary of results",
      "level": 3,
      "pageStart": 25,
      "pageEnd": 26,
      "labelStart": "17",
      "labelEnd": "18",
      "words": 175,
      "summary": {
        "text": "Reports widely varying rates of positive skin tests and IGRAs among contacts across studies and groups, with generally comparable detection of latent TB. It notes manufacturer support for some studies, including kit donations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst seemed",
          "heading": false
        },
        {
          "term": "both igras",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        },
        {
          "term": "varied",
          "heading": false
        },
        {
          "term": "ranged",
          "heading": false
        },
        {
          "term": "assays",
          "heading": false
        }
      ],
      "extract": "Summary of results Results indicated that in low- and middle-income countries:  The prevalence of positive tests varied greatly between studies and across assays. Prevalence of positive TST results ranged from 22% in children less than 5yrs to 84% in adult HCWs exposed to a smear-positive TB case. Prevalence of positive IGRA results ranged from 10% to 75% respectively. The majority of studies showed comparable LTBI",
      "extractCut": true
    },
    {
      "id": "sec-029-353-strengths-and-limitations-of-the-evidence-ba",
      "number": "3.5.3",
      "title": "Strengths and limitations of the evidence base",
      "level": 3,
      "pageStart": 26,
      "pageEnd": 26,
      "labelStart": "18",
      "labelEnd": "18",
      "words": 65,
      "summary": {
        "text": "Explains that data on contact screening could not be pooled because of heterogeneity, and that most studies were cross-sectional with inconsistent exposure categories.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "strengths",
          "heading": true
        },
        {
          "term": "limitations",
          "heading": true
        },
        {
          "term": "categorisation",
          "heading": false
        }
      ],
      "extract": "Strengths and limitations of the evidence base Due to significant heterogeneity in study designs and outcomes assessed in each study, it was not appropriate to pool the data. The majority of studies were cross-sectional and looked at concordance between TST and IGRAs. Studies that assessed associations between exposure and test positivity used different categorisation of exposure variables, making it difficult to",
      "extractCut": true
    },
    {
      "id": "sec-030-354-grade-evidence-profiles-and-final-policy-rec",
      "number": "3.5.4",
      "title": "Grade evidence profiles and final policy recommendations",
      "level": 3,
      "pageStart": 26,
      "pageEnd": 27,
      "labelStart": "18",
      "labelEnd": "19",
      "words": 112,
      "summary": {
        "text": "Presents the strong recommendation that IGRAs not replace the skin test for latent TB screening of adult and child contacts or in outbreak investigations in low- and middle-income countries.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence profiles",
          "heading": true
        },
        {
          "term": "grade evidence",
          "heading": true
        },
        {
          "term": "outbreak investigations",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        }
      ],
      "extract": "Grade evidence profiles and final policy recommendations The GRADE evidence profiles are provided in Table 11. Based on these assessments, the Expert Group concluded that the quality of evidence for use of IGRAS for LTBI screening in contact and outbreak investigations was very low and recommended that these tests should not be used in low- and middle-income countries as a replacement for TST, neither in adults nor",
      "extractCut": true
    },
    {
      "id": "sec-031-36-the-predictive-value-of-igras-for-incident-ac",
      "number": "3.6",
      "title": "The predictive value of IGRAs for incident active TB",
      "level": 2,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 9,
      "summary": {
        "text": "A section heading for the predictive value of IGRAs for incident active TB.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "The predictive value of IGRAs for incident active TB",
      "extractCut": false
    },
    {
      "id": "sec-032-361-study-characteristics",
      "number": "3.6.1",
      "title": "Study characteristics",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 126,
      "summary": {
        "text": "Describes the three eligible studies on whether IGRAs predict progression to active TB in low- and middle-income countries, noting differing populations and risks of verification and incorporation bias.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "school-going",
          "heading": false
        },
        {
          "term": "study",
          "heading": true
        },
        {
          "term": "ascertainment",
          "heading": false
        }
      ],
      "extract": "Study characteristics The initial search yielded 722 citations. After full-text review of 14 papers evaluating the predictive value of commercial IGRAs for active TB, 8 studies conducted in high-income countries were excluded, as were three studies using in-house IGRAs. Three studies were deemed to have met the eligibility criteria. The at-risk populations included in the three studies were all different (older",
      "extractCut": true
    },
    {
      "id": "sec-033-362-summary-of-results",
      "number": "3.6.2",
      "title": "Summary of results",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 27,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 201,
      "summary": {
        "text": "Reports that over 95% of people with positive IGRAs did not develop active TB during follow-up. IGRAs and the skin test performed comparably in predicting disease.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "tst sensitivity",
          "heading": false
        },
        {
          "term": "country study",
          "heading": false
        },
        {
          "term": "study population",
          "heading": false
        },
        {
          "term": "modest",
          "heading": false
        },
        {
          "term": "igra",
          "heading": false
        }
      ],
      "extract": "Summary of results Results indicated that in low- and middle-income countries:  The vast majority of individuals (>95%) with a positive IGRA results did not progress to active TB disease during follow-up, although a modest but statistically insignificant increase in incidence rates of TB in IGRA- positives compared to IGRA-negatives had been observed;  IGRA sensitivity for incident TB ranged from 75% to 88% (95%",
      "extractCut": true
    },
    {
      "id": "sec-034-363-grade-evidence-profiles-and-final-policy-rec",
      "number": "3.6.3",
      "title": "Grade evidence profiles and final policy recommendations",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 28,
      "labelStart": "19",
      "labelEnd": "20",
      "words": 101,
      "summary": {
        "text": "Presents the strong recommendation that neither IGRAs nor the skin test be used in low- and middle-income settings to predict which individuals will develop active TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "evidence profiles",
          "heading": true
        },
        {
          "term": "grade evidence",
          "heading": true
        },
        {
          "term": "strong recommendation",
          "heading": false
        }
      ],
      "extract": "Grade evidence profiles and final policy recommendations The GRADE evidence profiles are provided in Table 12 and 13. Based on these assessments, the Expert Group concluded that the quality of evidence for the predictive value of IGRAs was very low and recommended that these assays should not be used in low- and middle-income countries to identify individuals at risk of active TB disease(strong recommendation). The",
      "extractCut": true
    },
    {
      "id": "sec-035-4-operational-aspects-on-the-use-of-igras",
      "number": "4",
      "title": "Operational aspects on the use of IGRAs",
      "level": 1,
      "pageStart": 28,
      "pageEnd": 28,
      "labelStart": "20",
      "labelEnd": "20",
      "words": 339,
      "summary": {
        "text": "Summarizes the limited evidence on operational aspects of IGRAs, such as high cost, reproducibility and indeterminate results, and their need for well-equipped laboratories and trained staff. It contrasts these with the skin test's practical limitations.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "igras",
          "heading": true
        },
        {
          "term": "transport times",
          "heading": false
        },
        {
          "term": "hrs",
          "heading": false
        },
        {
          "term": "igra test",
          "heading": false
        },
        {
          "term": "studies reported",
          "heading": false
        },
        {
          "term": "reproducibility",
          "heading": false
        },
        {
          "term": "aspects",
          "heading": true
        },
        {
          "term": "t-spot",
          "heading": false
        }
      ],
      "extract": "Operational aspects on the use of IGRAs Only a few studies addressed these aspects, mainly in the discussion and not systematically:  Cost Cost of IGRAs was mentioned by four studies, stating that the assays are too expensive and therefore a limitation to their use.  Reproducibility Only one study addressed reproducibility of T-SPOT by assessing inter-observer agreement, showing excellent correlation. No other",
      "extractCut": true
    },
    {
      "id": "sec-036-5-overall-conclusions",
      "number": "5",
      "title": "Overall conclusions",
      "level": 1,
      "pageStart": 28,
      "pageEnd": 29,
      "labelStart": "20",
      "labelEnd": "21",
      "words": 99,
      "summary": {
        "text": "Sets out the overall conclusions that evidence on IGRAs in low- and middle-income countries is limited and of low quality, neither test predicts progression or diagnoses active TB, and replacing the skin test with costlier IGRAs is not recommended.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "igras",
          "heading": false
        },
        {
          "term": "tst",
          "heading": false
        },
        {
          "term": "conclusions",
          "heading": true
        }
      ],
      "extract": "Overall conclusions  There is insufficient data and low quality evidence on the performance of IGRAs in low- and middle-income countries, typically those with a high TB and/or HIV burden;  IGRAs and the TST cannot accurately predict the risk of infected individuals developing active TB disease; 21  Neither IGRAs nor the TST should be used for the diagnosis of active TB disease;  IGRAs are more costly and",
      "extractCut": true
    },
    {
      "id": "sec-037-6-implications-for-further-research",
      "number": "6",
      "title": "Implications for further research",
      "level": 1,
      "pageStart": 29,
      "pageEnd": 29,
      "labelStart": "21",
      "labelEnd": "21",
      "words": 68,
      "summary": {
        "text": "Calls for well-designed research on more accurate IGRAs, including representative populations, prospective follow-up, blinding and evaluation of patient impact.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "further research",
          "heading": true
        },
        {
          "term": "proof-of-principle",
          "heading": false
        },
        {
          "term": "implications",
          "heading": true
        }
      ],
      "extract": "Implications for further research Targeted further research to identify IGRAs with improved accuracy is strongly encouraged. Such research should be based on adequate study design and including quality principles such as representative suspect populations, prospective follow-up and adequate, explicit blinding. It is also strongly recommended that proof-of-principle studies be followed by evidence produced from",
      "extractCut": true
    },
    {
      "id": "sec-038-7-grade-tables",
      "number": "7",
      "title": "GRADE tables",
      "level": 1,
      "pageStart": 29,
      "pageEnd": 31,
      "labelStart": "21",
      "labelEnd": "23",
      "words": 307,
      "summary": {
        "text": "Lists the GRADE evidence profiles and summary-of-findings tables supporting the IGRA recommendations, covering active TB, children, people with HIV, health care workers, contacts and predictive value.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "grade",
          "heading": true
        },
        {
          "term": "findings igras",
          "heading": false
        },
        {
          "term": "middle-income countries",
          "heading": false
        },
        {
          "term": "grade evidence",
          "heading": false
        },
        {
          "term": "grade summary",
          "heading": false
        },
        {
          "term": "evidence profile",
          "heading": false
        },
        {
          "term": "latent tuberculosis",
          "heading": false
        },
        {
          "term": "active tuberculosis",
          "heading": false
        }
      ],
      "extract": "GRADE tables Table 1. GRADE Evidence Profile: Diagnostic accuracy of currently available commercial interferon gamma release assays (Quantiferon –TB Gold in –Tube [QFT-GIT ], Cellestis, Australia and T- SPOT.TB [T-SPOT], Oxford Immunotec, United Kingdom) for evaluation of patients with pulmonary TB in low- and middle-income countries (LMIC). Table 2. GRADE Summary of Findings – Role of IGRAs for evaluation of",
      "extractCut": true
    },
    {
      "id": "sec-039-8-selected-references",
      "number": "8",
      "title": "Selected references",
      "level": 1,
      "pageStart": 31,
      "pageEnd": 65,
      "labelStart": "23",
      "labelEnd": "57",
      "words": 12664,
      "summary": {
        "text": "The selected references for the IGRA policy statement, citing mainly the systematic reviews and meta-analyses on IGRAs in active TB, children, HIV, health care workers and contacts. The extracted block also runs into the GRADE evidence tables. These set out study numbers, quality ratings and findings for each outcome. Its final rows note that no studies addressed serial IGRA testing to predict active TB.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "qft-g qft-git",
          "heading": false
        },
        {
          "term": "points subtracted",
          "heading": false
        },
        {
          "term": "evaluated qft-git",
          "heading": false
        },
        {
          "term": "both qft-g",
          "heading": false
        },
        {
          "term": "igra conversions",
          "heading": false
        },
        {
          "term": "evaluated t-spot",
          "heading": false
        },
        {
          "term": "serious heterogeneity",
          "heading": false
        },
        {
          "term": "serious limitations",
          "heading": false
        }
      ],
      "extract": "Selected references 1. Metcalfe J, Everett C, Steingart K, Cattamanchi A, Huang L, Hopewell P, Pai M. Interferon – gamma release assays for active pulmonary TB diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. JID 2011; 204(suppl 4), November 15. 2. Mandalakas A, Detjen A, Hessling A, Bendetti A, Menzies D. Interferon-gamma release assays and childhood tuberculosis:",
      "extractCut": true
    },
    {
      "id": "sec-040-annex-1-list-of-participants---expert-group-meet",
      "number": "Annex 1",
      "title": "List of Participants - Expert Group meeting",
      "level": 1,
      "pageStart": 65,
      "pageEnd": 68,
      "labelStart": "57",
      "labelEnd": "60",
      "words": 580,
      "summary": {
        "text": "The list of participants at the July 2010 Geneva Expert Group meeting on IGRAs in TB control in low- and middle-income settings, with their affiliations and contact details, including WHO staff.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "stb tbl",
          "heading": false
        },
        {
          "term": "san francisco",
          "heading": false
        },
        {
          "term": "road mailstop",
          "heading": false
        },
        {
          "term": "clifton road",
          "heading": false
        },
        {
          "term": "ave",
          "heading": false
        },
        {
          "term": "bacterial pathogens",
          "heading": false
        },
        {
          "term": "prevention clifton",
          "heading": false
        },
        {
          "term": "ucsf",
          "heading": false
        }
      ],
      "extract": "Expert Group meeting on use of interferon-γ release assays (IGRAs) in tuberculosis control in low- and middle-income settings Geneva, Switzerland, 19-20 July 2010 Dr Richard A Adegbola Senior Program Officer Infectious Diseases, Global Health Bill & Melinda Gates Foundation P O Box 23350 Seattle, WA 98102 USA Richard.adegbola@gatesfoundation.org Dr Catharina Boehme Foundation for New Innovative New Diagnostics",
      "extractCut": true
    },
    {
      "id": "sec-041-annex-2-list-of-participants---stag-tb",
      "number": "Annex 2",
      "title": "List of Participants - STAG-TB",
      "level": 1,
      "pageStart": 68,
      "pageEnd": 70,
      "labelStart": "60",
      "labelEnd": null,
      "words": 366,
      "summary": {
        "text": "Lists the participants of the 10th meeting of WHO's Strategic and Technical Advisory Group for Tuberculosis (STAG-TB), held in Geneva on 27–29 September 2010, with their titles, institutions and countries, followed by the report's ISBN.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "stag-tb",
          "heading": true
        },
        {
          "term": "national center",
          "heading": false
        },
        {
          "term": "russian federation",
          "heading": false
        },
        {
          "term": "director",
          "heading": false
        },
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "disease control",
          "heading": false
        },
        {
          "term": "prof",
          "heading": false
        },
        {
          "term": "usa",
          "heading": false
        }
      ],
      "extract": "10th Meeting Strategic and Technical Advisory Group for Tuberculosis (STAG-TB) 27-29 September 2010, WHO Headquarters, Geneva, Switzerland Dr Salah Al Awaidy Director Department of Communicable Disease Surveillance & Control Oman Dr Kenneth Castro Director, Division of TB Elimination Centers for Disease Control and Prevention USA Dr Jeremiah Muhwa Chakaya (STAG-TB Chair) Technical Expert National Leprosy and TB",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "commercial igras",
      "heading": false
    },
    {
      "term": "igras performed",
      "heading": false
    },
    {
      "term": "based igras",
      "heading": false
    },
    {
      "term": "igras nor",
      "heading": false
    },
    {
      "term": "both igras",
      "heading": false
    },
    {
      "term": "findings igras",
      "heading": true
    },
    {
      "term": "neither igras",
      "heading": false
    },
    {
      "term": "evaluating igras",
      "heading": false
    },
    {
      "term": "igras appeared",
      "heading": false
    },
    {
      "term": "because igras",
      "heading": false
    },
    {
      "term": "in-house igras",
      "heading": false
    },
    {
      "term": "igra tst",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 2,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 3,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 4,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 5,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 6,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 7,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 8,
      "label": null,
      "source": null,
      "confidence": 0
    },
    {
      "physical": 9,
      "label": "1",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "2",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 11,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 12,
      "label": "4",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 13,
      "label": "5",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 14,
      "label": "6",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "8",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "9",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 18,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 19,
      "label": "11",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "12",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 21,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 22,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "15",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 24,
      "label": "16",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "18",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "19",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 28,
      "label": "20",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 29,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "22",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 31,
      "label": "23",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 32,
      "label": "24",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 33,
      "label": "25",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 34,
      "label": "26",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 35,
      "label": "27",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 36,
      "label": "28",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 37,
      "label": "29",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 38,
      "label": "30",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 39,
      "label": "31",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 40,
      "label": "32",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 41,
      "label": "33",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 42,
      "label": "34",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 43,
      "label": "35",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 44,
      "label": "36",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 45,
      "label": "37",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 46,
      "label": "38",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 47,
      "label": "39",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 48,
      "label": "40",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 49,
      "label": "41",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 50,
      "label": "42",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 51,
      "label": "43",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 52,
      "label": "44",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 53,
      "label": "45",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 54,
      "label": "46",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 55,
      "label": "47",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 56,
      "label": "48",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 57,
      "label": "49",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 58,
      "label": "50",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 59,
      "label": "51",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 60,
      "label": "52",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 61,
      "label": "53",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 62,
      "label": "54",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 63,
      "label": "55",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 64,
      "label": "56",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 65,
      "label": "57",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 66,
      "label": "58",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 67,
      "label": "59",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 68,
      "label": "60",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 69,
      "label": "61",
      "source": "printed",
      "confidence": 0.7
    },
    {
      "physical": 70,
      "label": null,
      "source": null,
      "confidence": 0
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "1",
      "title": "GRADE Evidence Profile: Diagnostic accuracy of currently available commercial interferon gamma release assays (Quantiferon –TB Gold in –Tube [QFT-GIT ], Cellestis, Australia and T- SPOT.TB [T-SPOT], Oxford Immunotec, United Kingdom) for evaluation of patients with pulmonary TB in lowand middle-incom",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "GRADE Summary of Findings – Role of IGRAs for evaluation of patients with pulmonary TB in lowand middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "GRADE Evidence Profile: The performance of IGRAs for the diagnosis of latent tuberculosis infection in children in lowand middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "GRADE Summary of Findings – IGRAs for the diagnosis of latent tuberculosis infection in children in lowand middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5",
      "title": "GRADE Evidence Profile: The diagnostic accuracy of IGRAs for the diagnosis of active tuberculosis in children in lowand middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6",
      "title": "GRADE Summary of Findings – IGRAs for the diagnosis of active tuberculosis in children in lowand middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7",
      "title": "GRADE Evidence Profile: The role of IGRAs in the diagnosis of latent tuberculosis infection in HIV-infected individuals in lowand middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "8",
      "title": "GRADE Summary of Findings – Role of IGRAs in the diagnosis of latent tuberculosis infection in HIV-infected individuals in lowand middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "9",
      "title": "GRADE Evidence Profile: IGRAs for tuberculosis screening of healthcare workers in low and middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "10",
      "title": "GRADE Summary of Findings – IGRAs for tuberculosis screening of healthcare workers in low and middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "11",
      "title": "GRADE Evidence Profile: Performance of IGRAs for the diagnosis of LTBI in contacts of active TB in low-and middle-income countries",
      "page": 29,
      "pageLabel": "21",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "12",
      "title": "GRADE Evidence Profile: Predictive value of commercial IGRA for incident active TB in low and middle-Income countries",
      "page": 30,
      "pageLabel": "22",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "13",
      "title": "GRADE Summary of Findings – Predictive value of commercial IGRA for incident active TB in low and middle-income countries",
      "page": 30,
      "pageLabel": "22",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. GRADE Evidence Profile: Diagnostic accuracy of currently available commercial interferon-gamma release assays (QuantiFERON-TB Gold In-Tube [QFT-GIT], Cellestis, Australia and T-SPOT.TB [T-SPOT], Oxford Immunotec, United Kingdom) for evaluation of patients with pulmonary TB in low- and middle-income countries",
      "pages": [
        32,
        33
      ],
      "columns": [
        {
          "titles": "No of Participants (studies)"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Limitations"
        },
        {
          "titles": "Indirectness"
        },
        {
          "titles": "Inconsistency"
        },
        {
          "titles": "Imprecision"
        },
        {
          "titles": "Publication Bias"
        },
        {
          "titles": "Quality of evidence (GRADE)"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "A. Outcome: Diagnostic accuracy",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "True Positives",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2067 (19) A1",
          "Cross-sectional",
          "No Serious Limitation A2",
          "No Serious Indirectness A3",
          "Serious A4 (-1)",
          "Serious A5 (-1)",
          "Likely A6",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ],
        [
          "True Negatives",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2067 (19) A1",
          "Cross-sectional",
          "No Serious Limitation A2",
          "No Serious Indirectness A3",
          "Serious A4 (-1)",
          "Serious A5 (-1)",
          "Likely A6",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ],
        [
          "False Positives",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2067 (19) A1",
          "Cross-sectional",
          "No Serious Limitation A2",
          "No Serious Indirectness A3",
          "Serious A4 (-1)",
          "Serious A5 (-1)",
          "Likely A6",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ],
        [
          "False Negatives",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2067 (19) A1",
          "Cross-sectional",
          "No Serious Limitation A2",
          "No Serious Indirectness A3",
          "Serious A4 (-1)",
          "Serious A5 (-1)",
          "Likely A6",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ],
        [
          "B. Outcome: Proportion indeterminate tests",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2872 (33) B1",
          "Cross-sectional",
          "Serious B2 (-1)",
          "No Serious Indirectness B3",
          "Serious B4 (-1)",
          "No Serious Imprecision B5",
          "Likely B6",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ],
        [
          "C. Outcome: Incremental value",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "943 (2) C1",
          "Cohort",
          "Serious C2 (-1)",
          "No Serious Indirectness C3",
          "No Serious Inconsistency C4",
          "Serious C5 (-1)",
          "Unlikely C6",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ]
      ],
      "notes": "Footnotes: 1 Quality of evidence was rated as high (no points subtracted), moderate (1 point subtracted), low (2 points subtracted), or very low (>2 points subtracted) based on five criteria: study limitations, indirectness of evidence, inconsistency in results across studies, imprecision in summary estimates, and likelihood of publication bias. For each outcome, the quality of evidence started at high when there were randomized controlled trials or high quality observational studies (cross-sectional or cohort studies enrolling patients with diagnostic uncertainty) and at moderate when these types of studies were absent. One point was then subtracted when there was a serious issue identified or two points when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. The evidence rankings were considered to be the same for consideration of true positives, false positives, false negatives, and true negatives. A1 Sensitivity and specificity were determined exclusively among active TB suspects. 19 studies (11 of QFT-GIT and 8 of T-SPOT) were included that assessed the specificity of IGRAs in patients with suspected active TB. A2 Study limitations were assessed using the QUADAS tool. Three (16%) studies did not enroll a representative spectrum of patients. Five (26%) studies did not clearly report that assessment of the reference standard was performed blinded to IGRA results. A3 Diagnostic accuracy was considered as a surrogate for patient-important outcomes. No studies measured the impact of IGRAs on patient-important outcomes among TB suspects randomized to treatment based on IGRA results; however, the Expert Group members voted not to downgrade for this factor, in part due to the low likelihood of such studies being undertaken. A4 Heterogeneity of studies is visually apparent in the Hierarchical Summary Receiver Operating Characteristics (HSROC) Plots. A5 Pooled sensitivity derived from the highest quality data (studies enrolling active TB suspects) had relatively wide confidence intervals for T-SPOT.TB (sensitivity 83% (95% CI 70-91%)) and QFT-GIT (sensitivity 73% (95% CI 61-82%)). Pooled specificity had wide confidence intervals for T-SPOT.TB (specificity 58% (95% CI 42-73%)) and acceptable confidence intervals for QFT-GIT (specificity 49% (95% CI 40-58%)). A6 Data included in the review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests, and publication bias cannot be ruled out. Although points were not deducted, a degree of publication bias is likely because: 1) literature on IGRAs is expanding rapidly; 2) anecdotal examples of unpublished negative studies on IGRAs exist; and 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. B1 33 studies were identified (21 of QFT-GIT and 12 of T-SPOT) from which proportions of indeterminate IGRA results could be derived. B2 Study limitations were assessed using the QUADAS tool. Seventeen (52%) studies did not enroll a representative spectrum of patients. B3 Please see footnote A3. B4 Pooled proportions of indeterminate results showed substantial heterogeneity for HIV-uninfected subjects evaluated with QFT-GIT (range 0-27%, I2 78%, p<0.001), and HIV-infected subjects evaluated with both QFT-GIT (range 3-40%, I2 72%, p<0.001) and T-SPOT (range 0-25%, I2 88%, p<0.001). B5 Precision was acceptable for both IGRAs in both HIV-infected (+/-7%) and HIV-uninfected (+/-3%) subjects. B6 Please see footnote A6. C1 Two completed but unpublished studies were identified (1 QFT-GIT and TSPOT, 1 QFT-GIT) that used multivariate methods to estimate the added value of IGRAs beyond conventional tests for active TB diagnosis. C2 As assessed by QUADAS criteria, one (50%) study did not enroll a representative spectrum of patients. Model specification was undertaken for both studies using traditional parametric statistical methods. C3 See footnote A3. In addition, area under the receiver-operating-characteristic curve (AUC) may be a less clinically interpretable measure of risk assessment than risk-reclassification statistics. C4 Only two studies were available; effect estimates for both studies were in the same direction and consistent. C5 Imprecision, as evaluated by 95% confidence intervals of the area under the receiver-operating-characteristic curves (AUC), was reasonable for both studies. C6 Because of the relative novelty of these methods, at this time it is unlikely that studies of IGRA incremental value have been unpublished due to publication bias. [Batch job pointed to p29, which only lists the GRADE table captions; the table itself is on p32 with footnotes on p33.]",
      "narratives": {
        "en": "GRADE evidence profile rating the quality of evidence on the diagnostic accuracy of commercial IGRAs (QFT-GIT and T-SPOT.TB) for pulmonary TB in low- and middle-income countries. For three outcomes (diagnostic accuracy as true/false positives and negatives, proportion of indeterminate tests, and incremental value), rows give the number of participants and studies, and columns the study design, limitations, indirectness, inconsistency, imprecision, publication bias, overall quality and importance.",
        "ar": "ملف بيّنات وفق منهجية GRADE يقيّم جودة البيّنات بشأن الدقة التشخيصية لمقايسات إطلاق الإنترفيرون غاما التجارية (QFT-GIT وT-SPOT.TB) في تشخيص السل الرئوي في البلدان المنخفضة والمتوسطة الدخل. ولكل من ثلاث حصائل (الدقة التشخيصية بحسب النتائج الإيجابية والسلبية الصحيحة والكاذبة، ونسبة الاختبارات غير الحاسمة، والقيمة الإضافية) تعرض الصفوف عدد المشاركين والدراسات، وتعرض الأعمدة تصميم الدراسة والقيود وعدم المباشرة وعدم الاتساق وعدم الدقة وتحيز النشر والجودة الإجمالية والأهمية.",
        "zh": "GRADE证据概况表，评价商品化γ干扰素释放试验（QFT-GIT和T-SPOT.TB）在中低收入国家诊断肺结核的准确性证据质量。针对三项结局（以真/假阳性和真/假阴性表示的诊断准确性、不确定结果比例和增量价值），各行列出参与者人数和研究数，各列为研究设计、局限性、间接性、不一致性、不精确性、发表偏倚、总体质量和重要性。",
        "es": "Perfil de evidencia GRADE que califica la calidad de la evidencia sobre la exactitud diagnóstica de los IGRA comerciales (QFT-GIT y T-SPOT.TB) para la tuberculosis pulmonar en países de ingresos bajos y medianos. Para tres resultados (exactitud diagnóstica como verdaderos y falsos positivos y negativos, proporción de pruebas indeterminadas y valor incremental), las filas indican el número de participantes y estudios, y las columnas el diseño del estudio, las limitaciones, el carácter indirecto, la incoherencia, la imprecisión, el sesgo de publicación, la calidad global y la importancia.",
        "fr": "Profil de données probantes GRADE évaluant la qualité des données sur l’exactitude diagnostique des tests IGRA commerciaux (QFT-GIT et T-SPOT.TB) pour la tuberculose pulmonaire dans les pays à revenu faible ou intermédiaire. Pour trois critères de jugement (exactitude diagnostique en vrais et faux positifs et négatifs, proportion de tests indéterminés et valeur ajoutée), les lignes donnent le nombre de participants et d’études, et les colonnes le plan d’étude, les limites, le caractère indirect, l’incohérence, l’imprécision, le biais de publication, la qualité globale et l’importance.",
        "ru": "Профиль доказательств GRADE, оценивающий качество данных о диагностической точности коммерческих тестов IGRA (QFT-GIT и T-SPOT.TB) при легочном туберкулезе в странах с низким и средним уровнем дохода. Для трех исходов (диагностическая точность в виде истинно и ложноположительных и отрицательных результатов, доля неопределенных результатов и дополнительная ценность) в строках указано число участников и исследований, а в столбцах — дизайн исследования, ограничения, косвенность, несогласованность, неточность, публикационная систематическая ошибка, общее качество и значимость."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. GRADE Summary of Findings – Role of IGRAs for evaluation of patients with pulmonary TB in low- and middle-income countries",
      "pages": [
        34,
        35,
        36
      ],
      "columns": [
        {
          "titles": "Outcomes: TP, TN, FP, FN / Subgroups"
        },
        {
          "titles": "Effect % (95% CI)"
        },
        {
          "titles": "No. of participants (studies)"
        },
        {
          "titles": "What do these results mean given 10% prevalence among suspects being screened for TB?"
        },
        {
          "titles": "What do these results mean given 30% prevalence among suspects being screened for TB?"
        },
        {
          "titles": "Quality of Evidence"
        }
      ],
      "rows": [
        [
          "T-SPOT.TB; HIV-infected",
          "Sensitivity 78% (56, 91) Specificity 55% (45, 64)",
          "549 (5)",
          "With a prevalence of 10%, 100/1000 will have TB. Of these, 78 (TP) will be identified; 22 (FN) will be missed by T-SPOT.TB. Of the 900 patients without TB, 495 (TN) will not be treated; 405 (FP) will be unnecessarily treated.",
          "With a prevalence of 30%, 300/1000 will have TB. Of these, 234 (TP) will be identified; 66 (FN) will be missed by T-SPOT.TB. Of the 700 patients without TB, 385 (TN) will not be treated; 315 (FP) will be unnecessarily treated.",
          "Low ⊕⊕○○"
        ],
        [
          "T-SPOT.TB; HIV-uninfected",
          "Insufficient data for pooled estimates",
          "364 (3)",
          "--",
          "--",
          "--"
        ],
        [
          "QuantiFERON-TB Gold In-Tube; HIV-infected",
          "Sensitivity 62% (41,79) Specificity 51% (39, 64)",
          "469 (6)",
          "With a prevalence of 10%, 100/1000 will have TB. Of these, 62 (TP) will be identified; 38 (FN) will be missed by QFT-GIT. Of the 900 patients without TB, 459 (TN) will not be treated; 441 (FP) will be unnecessarily treated.",
          "With a prevalence of 30%, 300/1000 will have TB. Of these, 186 (TP) will be identified; 114 (FN) will be missed by QFT-GIT. Of the 700 patients without TB, 357 (TN) will not be treated; 343 (FP) will be unnecessarily treated.",
          "Low ⊕⊕○○"
        ],
        [
          "QuantiFERON-TB Gold In-Tube; HIV-uninfected",
          "Sensitivity 82% (76, 87) Specificity 42% (33, 53)",
          "1304 (5)",
          "With a prevalence of 10%, 100/1000 will have TB. Of these, 82 (TP) will be identified; 18 (FN) will be missed by QFT-GIT. Of the 900 patients without TB, 378 (TN) will not be treated; 522 (FP) will be unnecessarily treated.",
          "With a prevalence of 30%, 300/1000 will have TB. Of these, 246 (TP) will be identified; 54 (FN) will be missed by QFT-GIT. Of the 700 patients without TB, 294 (TN) will not be treated; 406 (FP) will be unnecessarily treated.",
          "Low ⊕⊕○○"
        ],
        [
          "Outcome",
          "Subgroup",
          "Effect % (95% CI)",
          "No. of participants (studies)",
          "What do these findings mean?",
          "Quality of Evidence"
        ],
        [
          "IGRA-TST sensitivity difference*",
          "QuantiFERON-TB Gold In-Tube",
          "1% (-11 to 13%)*",
          "475 (10)",
          "This evidence suggests that QFT-GIT is no more sensitive than TST for active TB diagnosis in low- and middle-income countires.",
          "Low ⊕⊕○○"
        ],
        [
          "",
          "T-SPOT.TB",
          "9% (-10% to 28%)*",
          "206 (5)",
          "This evidence suggests that TSPOT is slightly more sensitive than TST for active TB diagnosis in low- and middle-income countries. This evidence should be interpreted with caution given the low number of studies available.",
          "Low ⊕⊕○○"
        ],
        [
          "Proportion indeterminate tests",
          "QuantiFERON-TB Gold In-Tube, HIV-uninfected Subjects",
          "4% (1-7%)",
          "1603 (11)",
          "This evidence suggests that among HIV-uninfected subjects, the proportion of indeterminate QFT-GIT test results in low- and middle-income countries will be low and similar to high-income countries.",
          "Low ⊕⊕○○"
        ],
        [
          "",
          "T-SPOT.TB, HIV-uninfected Subjects",
          "3% (1-4%)",
          "494 (5)",
          "This evidence suggests that among HIV-uninfected subjects, the proportion of indeterminate TSPOT test results in low- and middle-income countries will be low and similar to high-income countries.",
          "Low ⊕⊕○○"
        ],
        [
          "",
          "QuantiFERON-TB Gold In-Tube, HIV-infected Subjects",
          "16% (10-21%)",
          "728 (10)",
          "In low- and middle-income countries, the proportion of indeterminate QFT-GIT results among HIV-infected subjects can be expected to be high - in about 16% of the patients tested, clinicians will not be able to use the QFT results for decision making.",
          "Low ⊕⊕○○"
        ],
        [
          "",
          "T-SPOT.TB, HIV-infected Subjects",
          "8% (1-15%)",
          "666 (7)",
          "In low- and middle-income countries, the proportion of indeterminate TSPOT results among HIV-infected subjects can be expected to be high - in about 8% of patients tested, clinicians will not be able to use the TSPOT results for decision making.",
          "Low ⊕⊕○○"
        ],
        [
          "Incremental value",
          "Neither study demonstrated significant added value over conventional tests for active TB diagnosis, as measured by change in the area under receiver operating curve (AUC).",
          "",
          "943 (2)",
          "This evidence suggests that after consideration of readily available patient data, neither commercial IGRA can be expected to be useful in diagnosing active pulmonary TB in patients living in low-and middle-income countries.",
          "Low ⊕⊕○○"
        ]
      ],
      "notes": "Header block above the table: Review question: What is the diagnostic accuracy of commercial IGRAs for pulmonary tuberculosis? Patients/population: Adult pulmonary TB suspects and confirmed TB cases in low- and middle-income countries. Setting: Outpatients and inpatients. Index test: Commercial interferon-gamma release assays (QuantiFERON-TB Gold In-Tube [QFT-GIT], Cellestis, Australia and T-SPOT.TB [T-SPOT], Oxford Immunotec, United Kingdom). Importance: Rapid, accurate, simple test could supplement conventional microbiology and expand testing to peripheral health centers. Reference standard: Microbiologic (culture or smear-microscopy) or clinical diagnosis of pulmonary TB. Studies: Cross-sectional or cohort. Footnote: * Value is IGRA minus TST. [The table has a second header row mid-table (Outcome / Subgroup / Effect % (95% CI) / No. of participants (studies) / What do these findings mean? / Quality of Evidence), transcribed as body row 5; rows 6-12 follow that header. Batch job pointed to p29 (list of tables); table is on pp. 34-36.]",
      "narratives": {
        "en": "GRADE summary of findings on commercial IGRAs (T-SPOT.TB and QuantiFERON-TB Gold In-Tube) for evaluating pulmonary TB suspects in low- and middle-income countries. The first part gives pooled sensitivity and specificity by test and HIV status, with what they mean at 10% and 30% TB prevalence; the second part covers IGRA–TST sensitivity difference, proportion of indeterminate tests and incremental value, each with participants, interpretation and quality of evidence.",
        "ar": "ملخص نتائج وفق منهجية GRADE بشأن مقايسات إطلاق الإنترفيرون غاما التجارية (T-SPOT.TB وQuantiFERON-TB Gold In-Tube) لتقييم المشتبه في إصابتهم بالسل الرئوي في البلدان المنخفضة والمتوسطة الدخل. يعرض الجزء الأول الحساسية والنوعية المجمعتين بحسب الاختبار وحالة فيروس العوز المناعي البشري، ومدلولهما عند معدل انتشار للسل قدره 10% و30%؛ ويتناول الجزء الثاني الفرق في الحساسية بين المقايسات واختبار التوبركولين الجلدي، ونسبة الاختبارات غير الحاسمة، والقيمة الإضافية، مع عدد المشاركين والتفسير وجودة البيّنات.",
        "zh": "GRADE结果摘要表，涉及商品化γ干扰素释放试验（T-SPOT.TB和QuantiFERON-TB Gold In-Tube）在中低收入国家评估疑似肺结核患者的作用。第一部分按检测方法和艾滋病毒感染状况给出合并敏感性和特异性，以及在结核患病率为10%和30%时的含义；第二部分涉及IGRA与结核菌素皮肤试验的敏感性差异、不确定结果比例和增量价值，并列出参与者人数、解释和证据质量。",
        "es": "Resumen de resultados GRADE sobre los IGRA comerciales (T-SPOT.TB y QuantiFERON-TB Gold In-Tube) para evaluar a los casos sospechosos de tuberculosis pulmonar en países de ingresos bajos y medianos. La primera parte presenta la sensibilidad y especificidad combinadas por prueba y estado serológico respecto del VIH, y su significado con una prevalencia de tuberculosis del 10% y del 30%; la segunda abarca la diferencia de sensibilidad entre IGRA y PCT, la proporción de pruebas indeterminadas y el valor incremental, con participantes, interpretación y calidad de la evidencia.",
        "fr": "Synthèse des résultats GRADE sur les tests IGRA commerciaux (T-SPOT.TB et QuantiFERON-TB Gold In-Tube) pour l’évaluation des cas suspects de tuberculose pulmonaire dans les pays à revenu faible ou intermédiaire. La première partie présente la sensibilité et la spécificité poolées par test et selon le statut VIH, et leur signification pour une prévalence de la tuberculose de 10 % et de 30 % ; la seconde porte sur la différence de sensibilité IGRA–IDR, la proportion de tests indéterminés et la valeur ajoutée, avec participants, interprétation et qualité des données.",
        "ru": "Сводка результатов GRADE по коммерческим тестам IGRA (T-SPOT.TB и QuantiFERON-TB Gold In-Tube) для обследования лиц с подозрением на легочный туберкулез в странах с низким и средним уровнем дохода. В первой части приведены объединенные чувствительность и специфичность по тестам и ВИЧ-статусу и их значение при распространенности туберкулеза 10% и 30%; во второй — разница чувствительности IGRA и ТКП, доля неопределенных результатов и дополнительная ценность, с числом участников, интерпретацией и качеством доказательств."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. GRADE Evidence Profile: The performance of IGRAs for the diagnosis of latent tuberculosis infection in children in low- and middle-income countries",
      "pages": [
        37,
        38
      ],
      "columns": [
        {
          "titles": "No of participants (studies)"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Limitations"
        },
        {
          "titles": "Indirectness"
        },
        {
          "titles": "Inconsistency"
        },
        {
          "titles": "Imprecision"
        },
        {
          "titles": "Publication bias"
        },
        {
          "titles": "Quality of evidence (GRADE)1"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "A. Risk of progression to active TB",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No studies in LMIC",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "B. Outcome: Performance of IGRAs in studies using a dichotomous measure of exposure as reference standard for LTBI (exposed/unexposed)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "229 (4) B1",
          "Mainly cross-sectional",
          "Not serious B2",
          "Not serious B3",
          "Serious B4 (-1)",
          "Very serious B5 (-2)",
          "Likely 2",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "C. Outcome: Performance of IGRAs in studies assessing different gradients of TB exposure as reference standard for LTBI",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1057 (5) C1",
          "Cross sectional",
          "Not serious C2",
          "Not serious C3",
          "Serious C4",
          "Very serious C5",
          "Likely 2",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ]
      ],
      "notes": "The proportion of indeterminate results as well as the influence of HIV-status and young age on IGRA performance were rated as important outcomes (4-6 points) for patients with suspected LTBI. However, due to the small number of studies no subgroup analysis for these outcomes was performed. Active TB was used as a surrogate measure for LTBI. Tables 10 and 11 describe the evidence profile and summary of findings for studies assessing IGRAs in active TB suspects. Footnotes 1 The quality of evidence was rated as high (no points subtracted), moderate (1 point subtracted), low (2 points subtracted), or very low (>2 points subtracted) based on five criteria: study limitations, indirectness of evidence, inconsistency in results across studies, imprecision in summary estimates, and likelihood of publication bias. For each outcome, the quality of evidence started at high, when there were randomized controlled trials or high quality observational studies (cross-sectional or cohort studies enrolling patients with diagnostic uncertainty) and at moderate, when these types of studies were absent. One point was then subtracted when there was a serious issue identified or two points, when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. 2 Data included did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias cannot be ruled out. Although no points were deducted, a degree of publication bias is likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future; 2) there are anecdotal examples of unpublished negative studies on IGRAs; and 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. B1 Four studies identified: One evaluated T-SPOT, two evaluated T-SPOT and QFT-G, one evaluated T-SPOT and QFT-GIT. In total, QFT-G or QFT-GIT was evaluated in 59 children, T-SPOT in 170 children. B2 Study limitations were assessed using the QUADAS tool. Tw (50%) studies did not clearly enroll a representative spectrum (patient selection - random, consecutive or convenient - was not reported). Blinding of laboratory personnel was reported in 3/4 studies. Differential verification and execution of the reference standard were not considered important issues for exposure studies since all children were assessed for exposure. B3 a) All four studies were performed in upper middle-income countries; the data are not necessarily representative for low-income countries. b) TB exposure is a surrogate measure for patient important outcomes and does not necessarily classify the target condition (LTBI) correctly. Exposure increases the risk of infection and correctly identified children with infection will highly benefit from preventive chemotherapy. (No points subtracted) B4 Heterogeneity was assessed by looking at the variation between odds ratios for the different studies. For QFT-G/QFT-GIT the ORs varied between 0.43 and 5, for T-SPOT between 1.5 and 24. Differences in the definition of exposure groups between the studies may be responsible for the heterogeneity of the results. Two studies were performed in immune-compromised children, one in 100% HIV-infected children, the other in oncology patients. (1 point subtracted) B5 The 95% CIs for the odds of detecting exposed versus unexposed children were very wide for both QFT-G/QFT-GIT (1.30, 95%-CI 0.2-8.3) and T-SPOT (2.24, 95%-CI 0.88-5.64). The data available from LMIC was very limited and the sample size for exposure groups 3/4 studies was <50, some subgroups analyzed had a sample size of n=2, which highly increases the risk of imprecision. (2 points subtracted) C1 Five studies identified: two evaluated QFT-GIT (one without using a mitogen control), one evaluated QFT-G and one evaluated T-SPOT and QFT-GIT. In total, QFT-G or QFT-GIT was evaluated in 773 and T-SPOT in 225 children. C2 Study limitations were assessed using the QUADAS tool. One study assessed a representative spectrum of children and recruitment was performed in a consecutive manner. Blinding of laboratory technicians was reported in one study. Like for dichotomous exposure studies, differential verification and execution of the reference standard were not considered important issues for exposure studies since all children were assessed for exposure. C3 a) Three studies were performed in low-income countries, one in a lower-middle, one in an upper middle income country. b) TB exposure is a surrogate measure and does not necessarily classify the target condition (LTBI) correctly. Exposure increases the risk of infection and correctly identified children with infection will highly benefit from preventive chemotherapy. (No points subtracted) C4 Heterogeneity for T-SPOT could not be assessed since there was only one study. Heterogeneity for QFT was assessed using I-squared statistics and considered to be high (90%). Four studies used microbiological indicators (smear status), one used proximity to the index case as measure of exposure. (1 point subtracted) C5 The 95% CIs for the pooled random correlation between QFT-studies assessing exposure gradients were wide (QFT-G/QFT-GIT 0.28, 95%CI 0.06-0.86) For T-SPOT, the fixed correlation was 0.15, 95%CI 0.02-0.37. Similar, when calculating regression slopes for exposure gradients, confidence intervals were wide and overlapping for all tests assessed. The data available from LMIC was limited, and the sample sizes assessed small (2 points subtracted) [Batch job pointed to p29 (list of tables); table is on p37, footnotes continue on p38.]",
      "narratives": {
        "en": "GRADE evidence profile on the performance of IGRAs for diagnosing latent TB infection in children in low- and middle-income countries. For three outcomes (risk of progression to active TB, for which there were no studies in LMIC; performance against a dichotomous exposure reference; and performance against exposure gradients), it rates study design, limitations, indirectness, inconsistency, imprecision, publication bias, quality of evidence and importance.",
        "ar": "ملف بيّنات وفق منهجية GRADE بشأن أداء مقايسات إطلاق الإنترفيرون غاما في تشخيص العدوى الكامنة بالسل لدى الأطفال في البلدان المنخفضة والمتوسطة الدخل. ويقيّم لثلاث حصائل (خطر التطور إلى سل نشط، ولا توجد بشأنه دراسات في هذه البلدان؛ والأداء مقارنة بمعيار تعرض ثنائي؛ والأداء مقارنة بتدرجات التعرض) تصميم الدراسة والقيود وعدم المباشرة وعدم الاتساق وعدم الدقة وتحيز النشر وجودة البيّنات والأهمية.",
        "zh": "GRADE证据概况表，涉及γ干扰素释放试验在中低收入国家诊断儿童结核潜伏感染的表现。针对三项结局（进展为活动性结核的风险——中低收入国家无相关研究；以二分暴露为参照标准的表现；以暴露梯度为参照标准的表现），评价研究设计、局限性、间接性、不一致性、不精确性、发表偏倚、证据质量和重要性。",
        "es": "Perfil de evidencia GRADE sobre el desempeño de los IGRA para diagnosticar la infección tuberculosa latente en niños en países de ingresos bajos y medianos. Para tres resultados (riesgo de progresión a tuberculosis activa, sin estudios en estos países; desempeño frente a una medida dicotómica de exposición; y desempeño frente a gradientes de exposición) califica el diseño, las limitaciones, el carácter indirecto, la incoherencia, la imprecisión, el sesgo de publicación, la calidad de la evidencia y la importancia.",
        "fr": "Profil de données probantes GRADE sur la performance des tests IGRA pour le diagnostic de l’infection tuberculeuse latente chez l’enfant dans les pays à revenu faible ou intermédiaire. Pour trois critères (risque de progression vers une tuberculose active, sans étude dans ces pays ; performance par rapport à une mesure dichotomique de l’exposition ; performance par rapport à des gradients d’exposition), il évalue le plan d’étude, les limites, le caractère indirect, l’incohérence, l’imprécision, le biais de publication, la qualité des données et l’importance.",
        "ru": "Профиль доказательств GRADE об эффективности тестов IGRA для диагностики латентной туберкулезной инфекции у детей в странах с низким и средним уровнем дохода. Для трех исходов (риск прогрессирования в активный туберкулез — исследований в этих странах нет; эффективность относительно дихотомической меры контакта; эффективность относительно градиентов контакта) оцениваются дизайн, ограничения, косвенность, несогласованность, неточность, публикационная ошибка, качество доказательств и значимость."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4. GRADE Summary of Findings – IGRAs for the diagnosis of latent tuberculosis infection in children in low- and middle-income countries",
      "pages": [
        39
      ],
      "columns": [
        {
          "titles": "Outcome"
        },
        {
          "titles": "No. Participants"
        },
        {
          "titles": "Principal Findings"
        },
        {
          "titles": "What do these findings mean?"
        },
        {
          "titles": "Quality of Evidence"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "Predictive value for active TB",
          "No studies in LMIC",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "Performance of IGRAs against dichotomous measure of exposure",
          "QFT-G/QFT-GIT: 59 (3) T-SPOT: 170 (4) TST (10mm): 159 (3)",
          "Pooled Odds ratios • QFT-G/QFT-GIT: OR 1.30 (95% CI 0.20-8.32) • T-SPOT: OR 2.24 (95% CI 0.88-5.64) • TST (10mm): OR 0.81 (95% CI 0.38-1.74)",
          "Children exposed to TB have a higher risk of LTBI, expressed by a higher probability of a positive test for LTBI (QFT, T-SPOT or TST) than in unexposed children. Wide and overlapping confidence intervals indicate similar performance of all three tests.",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "Performance of IGRAs against exposure gradient",
          "QFT-G/QFT-GIT: 773 (5) T-SPOT: 225 (1) TST (10 mm) 871 (5)",
          "1. Pooled correlation between test and exposure gradient: • QFT-G/QFT-GIT: 0.28 (95%CI 0.06-0.86, I2 0.90) • T-SPOT (not pooled, 1 study): 0.15 (95% CI 0.02-0.37) • TST (10 mm): 0.22 (95% CI 0.11-0.39, I2 0.65) 2. Regression slopes • QFT-G/QFT-GIT: 1.84 (95%CI 1.38-2.44, I2 0.66) • T-SPOT: 1.63 (95%CI 1.12-2.39) • TST (10 mm): 1.73 (95% CI 1.36-2.20, I2 0.59)",
          "A higher level of exposure to TB indicates a higher risk for LTBI, expressed by a positive correlation between LTBI test and exposure gradients. IGRAs and TST show a similar correlation with exposure gradients (wide and overlapping confidence intervals).",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ]
      ],
      "notes": "Header block above the table: Review question: What is the performance of IGRAs for the detection of LTBI in children in LMIC? Patients/population: Children <18 years old in low, lower-middle and upper-middle income countries being screened for LTBI. Index test: QuantiFERON-TB Gold [QFT-G], QuantiFERON-TB Gold In-Tube [QFT-GIT], and T-SPOT.TB [T-SPOT]. Importance: Children have a high risk of progression to active TB after infection. Correctly identified children with LTBI benefit from preventive therapy. Reference standards: Incident TB, Exposure (dichotomous and gradient), prevalent TB. Studies: Observational studies (cohort, cross-sectional, case-control). [Batch job pointed to p29 (list of tables); table is on p39.]",
      "narratives": {
        "en": "GRADE summary of findings on IGRAs for diagnosing latent TB infection in children in low- and middle-income countries. Rows are outcomes (predictive value for active TB, performance against a dichotomous exposure measure, performance against exposure gradients); columns give participants per test, principal findings (pooled odds ratios, correlations, regression slopes for QFT, T-SPOT and TST), their meaning, quality of evidence and importance.",
        "ar": "ملخص نتائج وفق منهجية GRADE بشأن مقايسات إطلاق الإنترفيرون غاما لتشخيص العدوى الكامنة بالسل لدى الأطفال في البلدان المنخفضة والمتوسطة الدخل. تمثل الصفوف الحصائل (القيمة التنبؤية للسل النشط، والأداء مقارنة بمقياس تعرض ثنائي، والأداء مقارنة بتدرجات التعرض)، وتعرض الأعمدة عدد المشاركين لكل اختبار والنتائج الرئيسية (نسب الأرجحية المجمعة والارتباطات ومنحدرات الانحدار) ومدلولها وجودة البيّنات والأهمية.",
        "zh": "GRADE结果摘要表，涉及γ干扰素释放试验在中低收入国家诊断儿童结核潜伏感染。各行为结局（对活动性结核的预测价值、相对于二分暴露指标的表现、相对于暴露梯度的表现）；各列为各检测的参与者人数、主要结果（合并比值比、相关系数、回归斜率）、其含义、证据质量和重要性。",
        "es": "Resumen de resultados GRADE sobre los IGRA para diagnosticar la infección tuberculosa latente en niños en países de ingresos bajos y medianos. Las filas son los resultados (valor predictivo de tuberculosis activa, desempeño frente a una medida dicotómica de exposición y frente a gradientes de exposición); las columnas indican los participantes por prueba, los hallazgos principales (razones de posibilidades combinadas, correlaciones, pendientes de regresión), su significado, la calidad de la evidencia y la importancia.",
        "fr": "Synthèse des résultats GRADE sur les tests IGRA pour le diagnostic de l’infection tuberculeuse latente chez l’enfant dans les pays à revenu faible ou intermédiaire. Les lignes sont les critères (valeur prédictive de tuberculose active, performance par rapport à une mesure dichotomique et à des gradients d’exposition) ; les colonnes donnent les participants par test, les principaux résultats (odds ratios poolés, corrélations, pentes de régression), leur signification, la qualité des données et l’importance.",
        "ru": "Сводка результатов GRADE по тестам IGRA для диагностики латентной туберкулезной инфекции у детей в странах с низким и средним уровнем дохода. Строки — исходы (прогностическая ценность в отношении активного туберкулеза, эффективность относительно дихотомической меры и градиентов контакта); столбцы — число участников по тестам, основные результаты (объединенные отношения шансов, корреляции, наклоны регрессии), их значение, качество доказательств и значимость."
      },
      "csv": "tables/table-4.csv"
    },
    {
      "label": "Table 5",
      "caption": "Table 5. GRADE Evidence Profile: The diagnostic accuracy of IGRAs for the diagnosis of active tuberculosis in children in low- and middle-income countries",
      "pages": [
        40,
        41,
        42
      ],
      "columns": [
        {
          "titles": "No of Participants (Studies)"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Limitations"
        },
        {
          "titles": "Indirectness"
        },
        {
          "titles": "Inconsistency"
        },
        {
          "titles": "Imprecision"
        },
        {
          "titles": "Publication Bias"
        },
        {
          "titles": "Quality of Evidence (GRADE)1"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "A: What is the sensitivity of IGRAs in children with active TB?",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "207 (6) A1",
          "Mainly cross-sectional",
          "Serious A2 (-1)",
          "Not serious A3",
          "Not serious A4",
          "Very serious A5 (-2)",
          "Likely 2",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "B: What is the specificity of IGRAs in children without TB?",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "519 (4) B1",
          "Mainly cross-sectional",
          "Serious B2 (-1)",
          "Not serious B3",
          "Serious B4",
          "Serious B5 (-1)",
          "Likely 2",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "C What is the proportion of indeterminate IGRA results among children assessed for active TB?",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "656 (5) C1",
          "Mainly cross sectional",
          "Serious C2 (-1)",
          "Not serious C3",
          "Not serious C4",
          "Serious C5",
          "Likely 2",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "D: What is the diagnostic accuracy of IGRAs in HIV-infected children?",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "36 (1) D1",
          "Cross-sectional",
          "Serious D2 (1)",
          "Not serious D3",
          "Not applicable D4",
          "Very serious D5",
          "Likely 2",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "E: What is the diagnostic accuracy of IGRAs in children < 5 years?",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "471 (2) E1",
          "Cross-sectional",
          "Serious E2 (-1)",
          "Serious E3 Not serious",
          "Not applicable E4",
          "Very serious E5",
          "Likely 2",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ]
      ],
      "notes": "Footnotes 1 The quality of evidence was rated as high (no points subtracted), moderate (1 point subtracted), low (2 points subtracted), or very low (>2 points subtracted) based on five criteria: study limitations, indirectness of evidence, inconsistency in results across studies, imprecision in summary estimates, and likelihood of publication bias. For each outcome, the quality of evidence started at high, when there were randomized controlled trials or high quality observational studies (cross-sectional or cohort studies enrolling patients with diagnostic uncertainty) and at moderate, when these types of studies were absent. One point was then subtracted when there was a serious issue identified or two points, when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. 2 Data included did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias cannot be ruled out. Although no points were deducted a degree of publication bias is likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future; 2) there are anecdotal examples of unpublished negative studies on IGRAs; and 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. A1 6 studies identified for the assessment of sensitivity (TP and FN) of commercial IGRAs in children with suspected TB or active TB: 3 evaluated T-SPOT, 2 evaluated QFT-GIT, and 1 evaluated QFT-G. In total, 73 children were evaluated with QFT-G or QFT-GIT and 134 with T-SPOT. A2 Study limitations were assessed using QUADAS. One study described a representative spectrum with consecutive patient selection. In 2 studies it remained unclear whether differential verification was avoided. The execution of the reference standard (definition of active TB) was described in 5/6 studies but definition of the reference standard still varied between different studies and was described more clearly in some than others. Blinding of both laboratory technicians and clinicians remained unclear in the majority of studies. (1 point subtracted) A3 Four studies were performed in upper middle, 2 in lower middle-income countries and none in low income countries. Hence, the findings may not be generalisable to low-income countries. Diagnostic accuracy of IGRAs is only a surrogate for patient important outcomes. False negative tests result in children not being diagnosed and started on treatment, which will result in progression of disease, and potentially death. (No points subtracted). A4 The I2 statistics showed low to moderate heterogeneity among studies assessing QFT-G/QFT-GIT (32%) with sensitivities ranging from 50 to 63%. Sensitivities for three studies assessing T- SPOT ranged between 42 and 100%; I-squared was 0%, which may be due to the small number of studies included in the analysis. Indeterminate results, if added to false negative results, lowered the pooled sensitivity for both assays. It can be assumed that the heterogeneity among the studies is caused by factors such as differences in the study populations , number of confirmed versus probable TB cases included in the studies, disease severity, age groups and others. A5 The 95% confidence interval for pooled sensitivity was wide for both QFT-G/QFT-GIT (51%, 95% CI 38-63%) and T-SPOT (77%, 95% CI 23-100%). The data available from LMIC was very limited and sample sizes in the individual studies small. (2 points subtracted) B1 Four studies assessed specificity in children where active TB was excluded: 2 evaluated T-SPOT, and 2 QFT-GIT. In total, 422 children were evaluated with QFT-G or QFT-GIT, and 97 children with T-SPOT. B2 Study limitations were assessed using QUADAS. One study described recruitment of a representative spectrum of children in a consecutive manner. Differential verification was avoided in all studies, and the execution of the reference standard was described in the majority, even though with differing quality. Blinding of laboratory technicians and clinicians remained unclear in the majority of studies. (1 point subtracted) B3 None of the studies was performed in low-income countries, two in lower, and two in upper middle-income countries. Diagnostic accuracy of IGRAs is a surrogate for patient-important outcomes. False positive results can lead to a delay in making a correct diagnosis. IGRAs cannot differentiate between disease and infection and positive results may just reflect underlying TB infection. (No points subtracted) B4 Specificity for QFT-GIT ranged between 85 and 94%, the I2 statistics of 71% indicates that there is a considerable amount of heterogeneity and suggests that results should be interpreted with caution. For T-SPOT, specificity ranged between 84% and 98%, I2 statistics was 0 (again, this is likely due to the small number of studies included in this analysis). B5 The 95% CI for pooled specificity for QFT-G/QFT-GIT (90%, 95%CI 83-95) and T-SPOT (93%, 95%CI 83-100) were relatively narrow. However, the data available for LMIC was limited and the sample sizes of included studies small. (1 point subtracted) C1 5 studies assessed commercial IGRAs in children with suspected TB, active TB or ‘no TB’ and included indeterminate results: indeterminate results for QFT-G or QFT-GIT were reported in 3 studies among 524 children, indeterminate results for T-SPOT were reported in 2 studies among 132 children. C2 Study limitations were assessed using QUADAS. One study described recruitment of a representative spectrum of children in a consecutive manner. Differential verification was avoided and the execution of the reference standard (definition of active TB) was described in the majority. Blinding of both laboratory technicians and clinicians remained unclear in the majority of studies. (1 point subtracted) C3 Three studies were performed in upper middle, 2 in lower middle-income countries and none in low income countries. Hence, the findings may not be generalisable to low-income countries. Diagnostic accuracy of IGRAs is only a surrogate for patient important outcomes. False negative or indeterminate tests result in children not being diagnosed and started on treatment, which will result in progression of disease, and potentially death. (No points subtracted) C4 Heterogeneity was assessed by looking at the range of indeterminate results across studies. The overall proportion of indeterminates was 25% for QFT-G, 4.1 for QFT-GIT studies (range 0- 5% in individual studies) and 6.8% for T-SPOT (range 0-8% in individual studies). The QFT-G study showing 25% indeterminates was performed in 100% HIV-infected children with active TB and classifies a high-risk patient group that should be assessed separately for indeterminate results. (No points subtracted) C5 The number of studies from LMI assessing indeterminate results was limited and the sample size of study populations used for this analysis was small, accounting for serious imprecision. (1 point subtracted) D1 One study assessed QuantiFERON-TB Gold in 36 HIV-infected children with active TB in Romania (an upper middle-income country. D2 Study limitations were assessed using QUADAS. The spectrum of patients included in the study was not representative, patient selection was unclear. It also remained unclear whether laboratory technicians and clinicians were blinded. (1 point subtracted) D3 The study was performed among HIV-infected children with a diagnosis of TB in Romania, an upper middle-income country. The results may not be generalisable to low-income countries. Sensitivity of IGRAs is only a surrogate for patient-important outcomes. False negative results, particularly in HIV-infected children, may results in under-diagnosis of disease and, possibly in death. If indeterminate results were added to false negative results the sensitivity was lowered from 63% (indeterminates excluded) to 47% (95%CI 0-100). (No points subtracted) D4 Only one study – inconsistency therefore cannot be assessed. D5 The 95% CI for sensitivity of QFT-G in 36 HIV-infected children was very wide (63%, 95%CI 16-100). (2 points subtracted) E1 In 2 studies evaluating IGRAs for the diagnosis of active TB the mean or median age of children was below five years. One evaluated T-SPOT, and one QFT-GIT. QFT-GIT was assessed in 363 children (36 with active TB, 327 in ‘no TB’ group) and T-SPOT in 108 children (58 with active TB and 50 in ‘no TB’ group). E2 Study limitations were assessed using QUADAS. The spectrum and patient selection as well as blinding of laboratory technicians was unclear in both studies. Also, studies for this stratum were selected according to mean or median age since only few studies reported data stratified to age groups. (1 point subtracted) E3 Both studies were performed in upper middle-income countries, none in lower middle or low-income countries. Hence, the data may not be generalizable to low-income countries. Test accuracy is only a surrogate for patient-important outcomes. Children under 5 have the highest risk of severe disease and false negative results can result in fatal outcomes. At the same time, false positive results can result in misdiagnosis and prolong the time to correct diagnosis. (No points subtracted) E4 Heterogeneity could not be assessed since each test was only assessed in one study. E5 The confidence intervals for sensitivity and specificity of QFT-GIT were small, but wide for T-SPOT. The data from LMIC to address this objective was extremely limited. (2 points subtracted). [Batch job pointed to p29 (list of tables); table is on p40, footnotes continue to p42.]",
      "narratives": {
        "en": "GRADE evidence profile on the diagnostic accuracy of IGRAs for active TB in children in low- and middle-income countries. Five questions (sensitivity, specificity, proportion of indeterminate results, accuracy in HIV-infected children, accuracy in children under 5) are each rated for study design, limitations, indirectness, inconsistency, imprecision, publication bias, quality of evidence and importance.",
        "ar": "ملف بيّنات وفق منهجية GRADE بشأن الدقة التشخيصية لمقايسات إطلاق الإنترفيرون غاما للسل النشط لدى الأطفال في البلدان المنخفضة والمتوسطة الدخل. وتُقيَّم خمسة أسئلة (الحساسية، والنوعية، ونسبة النتائج غير الحاسمة، والدقة لدى الأطفال المصابين بفيروس العوز المناعي البشري، والدقة لدى الأطفال دون الخامسة) من حيث تصميم الدراسة والقيود وعدم المباشرة وعدم الاتساق وعدم الدقة وتحيز النشر وجودة البيّنات والأهمية.",
        "zh": "GRADE证据概况表，涉及γ干扰素释放试验在中低收入国家诊断儿童活动性结核的准确性。五个问题（敏感性、特异性、不确定结果比例、在感染艾滋病毒儿童中的准确性、在5岁以下儿童中的准确性）分别按研究设计、局限性、间接性、不一致性、不精确性、发表偏倚、证据质量和重要性进行评价。",
        "es": "Perfil de evidencia GRADE sobre la exactitud diagnóstica de los IGRA para la tuberculosis activa en niños en países de ingresos bajos y medianos. Cinco preguntas (sensibilidad, especificidad, proporción de resultados indeterminados, exactitud en niños con infección por el VIH y en menores de 5 años) se califican según diseño, limitaciones, carácter indirecto, incoherencia, imprecisión, sesgo de publicación, calidad de la evidencia e importancia.",
        "fr": "Profil de données probantes GRADE sur l’exactitude diagnostique des tests IGRA pour la tuberculose active chez l’enfant dans les pays à revenu faible ou intermédiaire. Cinq questions (sensibilité, spécificité, proportion de résultats indéterminés, exactitude chez l’enfant infecté par le VIH et chez l’enfant de moins de 5 ans) sont évaluées selon le plan d’étude, les limites, le caractère indirect, l’incohérence, l’imprécision, le biais de publication, la qualité des données et l’importance.",
        "ru": "Профиль доказательств GRADE о диагностической точности тестов IGRA при активном туберкулезе у детей в странах с низким и средним уровнем дохода. Пять вопросов (чувствительность, специфичность, доля неопределенных результатов, точность у ВИЧ-инфицированных детей и у детей до 5 лет) оцениваются по дизайну, ограничениям, косвенности, несогласованности, неточности, публикационной ошибке, качеству доказательств и значимости."
      },
      "csv": "tables/table-5.csv"
    },
    {
      "label": "Table 6",
      "caption": "Table 6. GRADE Summary of Findings – IGRAs for the diagnosis of active tuberculosis in children in low- and middle-income countries",
      "pages": [
        43,
        44,
        45,
        46
      ],
      "columns": [
        {
          "titles": "Outcome"
        },
        {
          "titles": "Index test"
        },
        {
          "titles": "No. of Participants (Studies)"
        },
        {
          "titles": "Effect % (95% CI) Main findings"
        },
        {
          "titles": "What do these results mean given a 10% prevalence among suspects being screened for TB?"
        },
        {
          "titles": "What do these results mean given a 30% prevalence among suspects being screened for TB?"
        },
        {
          "titles": "Quality of Evidence"
        }
      ],
      "rows": [
        [
          "What is the diagnostic accuracy of IGRAs for active TB?",
          "T-SPOT",
          "Sensitivity 143 (3) Specificity 97(2)",
          "Pooled sensitivity 77% (23-100) • Not considerably lower if indeterminate results counted as false negative 76% (18-100) Pooled specificity 93% (83-100) • Lower in population with >50% BCG coverage 85% (15-100)",
          "With a prevalence of 10%, 100/1000 children will have TB. Of these, 77 will be correctly identified with T-SPOT, 23 will be missed. Of 900 children without TB, 837 will not be treated, 63 will be unnecessarily treated.",
          "With a prevalence of 30%, 300/1000 will have TB. 231 will be correctly identified with T-SPOT, 69 will be missed. Of 700 children without TB, 651 will not be treated, 49 will be unnecessarily treated.",
          "Very Low ⊕○○○"
        ],
        [
          "",
          "QFT-G/ QFT-GIT",
          "Sensitivity 84 (3) Specificity 422 (2)",
          "Pooled sensitivity QFT-G, 1 study: 65% (47-82) QFT-GIT, 2 studies: 36% (29-44) Combined: 51% (38-63) • Pooled sensitivity including indeterminates for QFT-G and QFT-GIT 36% (23-49) Pooled specificity QFT-GIT 90% (83-95)",
          "With a prevalence of 10%, 100/1000 will have TB. Of these, 65 will be correctly identified by QFT-G, 35 will be missed. 36 will be identified by QFT-GIT, 64 will be missed. Indeterminate results lead to slightly more missed cases. Of 900 children without TB, 90 children will be unnecessarily treated based on QFT-GIT results.",
          "With a prevalence of 30%, 300/1000 will have TB. Of these, 195 will be correctly identified with QFT-G, 105 will be missed. 108 will be identified by QFT-GIT, 192 will be missed. Of 700 children without TB, 70 will be unnecessarily treated based on QFT-GIT results.",
          "Very Low ⊕○○○"
        ],
        [
          "",
          "TST",
          "Sensitivity 168 (5) Specificity 490 (3)",
          "Pooled sensitivity 65% (31-99) Pooled specificity 90% (82-98)",
          "IGRAs do not perform significantly different from TST",
          "",
          ""
        ],
        [
          "What is the proportion of indeterminate IGRAs among children assessed for active TB?",
          "T-SPOT",
          "132 (2)",
          "Indeterminates/total number of tests 9/132 = 6.82 % Range of % indeterminates across studies 0-8%",
          "What do these results mean? On average, indeterminate IGRA results are below 10% but can be high in certain populations, such as in one study performed in 100% HIV-infected children with active TB, showing 25% indeterminates.",
          "",
          "Very Low ⊕○○○"
        ],
        [
          "",
          "QFT-G/ QFT-GIT",
          "QFT-G 36 (1) QFT-GIT 488 (2)",
          "Indeterminates/total number of tests QFT-G: 9/36 = 25% QFT-GIT: 20/488=4.1% (Range of % indeterminates across studies 0-5%)",
          "",
          "",
          ""
        ],
        [
          "Performance of IGRAs in HIV-infected children",
          "T-SPOT",
          "No studies",
          "No studies",
          "",
          "",
          "Very Low ⊕○○○"
        ],
        [
          "",
          "QFT-G",
          "Sensitivity 36 (1) Specificity No studies",
          "Sensitivity QFT-G: 63% (16-100) • 47% (0-100) if indeterminates counted as FN Pooled specificity No studies",
          "With a prevalence of 10%, 100/1000 HIV-infected children will have TB. Of these, 63 will be correctly identified with QFT-G, 37 will be missed.",
          "With a prevalence of 30%, 300/1000 will have TB. Of these, 189 will be correctly identified with QFT-G, 111 will be missed.",
          ""
        ],
        [
          "",
          "TST",
          "Sensitivity 36 (1) Specificity No studies",
          "Sensitivity 39% (0-100) Specificity No studies",
          "Sensitivity of TST is lower than of QFT-G, but confidence intervals are wide and overlap.",
          "",
          ""
        ],
        [
          "Performance in children <5yrs",
          "T-SPOT",
          "Sensitivity 134 (3) Specificity 97 (2)",
          "Pooled sensitivity 77% (23-100) Pooled specificity 93% (83-100)",
          "With a prevalence of 10%, 100/1000 will have TB. Of these, 77 will be correctly identified by T-SPOT, 23 will be missed. Of 900 children without TB, 837 will not be treated and 63 will be unnecessarily treated.",
          "With a prevalence of 30%, 300/1000 will have TB. Of these, 231 will be correctly identified with T-SPOT, 69 will be missed. Of 700 children with out TB, 651 will not be treated, and 49 will be unnecessarily treated.",
          "Very Low ⊕○○○"
        ],
        [
          "",
          "QFT-GIT",
          "Sensitivity 36 (1) Specificity 327 (1)",
          "Pooled sensitivity 35% (30-40) Pooled specificity 85% (81-89)",
          "With a prevalence of 10%, 100/1000 will have TB. Of these, 35 will be correctly identified by QFT-GIT, 65 will be missed. Of 900 children without TB, 765 will not be treated, 135 will be unnecessarily treated.",
          "With a prevalence of 30%, 300/1000 will have TB. Of these, 105 will be correctly identified by QFT, 195 will be missed. Of 700 children without TB, 595 will not be treated, 105 will be unnecessarily treated.",
          ""
        ],
        [
          "",
          "TST",
          "Sensitivity 99 (2) Specificity 395 (2)",
          "Pooled sensitivity 41% (0-85) Pooled specificity 83% (81-86)",
          "Sensitivity and specificity of T-SPOT are higher than of QFT-GIT or TST, but the difference is not significant (overlapping confidence intervals)",
          "",
          ""
        ]
      ],
      "notes": "Header block above the table: Review question: What is the diagnostic accuracy of IGRAs for the diagnosis of active TB in children in LMIC? Patients/population: TB suspects or active TB patients and control group with ‘no TB’ in low and middle income countries. Setting: Mainly mixed, in- and outpatients. Index test: QuantiFERON-TB Gold [QFT-G], QuantiFERON-TB Gold In-Tube [QFT-GIT], and T-SPOT.TB [T-SPOT]. Importance: Diagnosis of childhood TB is often a composite of risk factors, clinical signs and symptoms and radiological imaging, since culture confirmation proves difficult. Highly sensitive assays would support a diagnosis of active TB. Reference standard: Culture confirmed TB and probable TB versus ‘no TB’. Studies: Cross-sectional or case-control studies. [Batch job pointed to p29 (list of tables); table runs pp. 43-46. On p45 the \"Very Low\" label sits in the top cell of the quality column and ⊕○○○ in the cell below; treated as one merged cell G6:G8.]",
      "narratives": {
        "en": "GRADE summary of findings on IGRAs (T-SPOT, QFT-G/QFT-GIT) compared with TST for diagnosing active TB in children in low- and middle-income countries. Rows cover overall diagnostic accuracy, proportion of indeterminate results, performance in HIV-infected children and performance in children under 5, by index test; columns give participants, pooled sensitivity/specificity or indeterminate rates, what the results mean at 10% and 30% prevalence, and quality of evidence.",
        "ar": "ملخص نتائج وفق منهجية GRADE بشأن مقايسات إطلاق الإنترفيرون غاما (T-SPOT وQFT-G/QFT-GIT) مقارنة باختبار التوبركولين الجلدي لتشخيص السل النشط لدى الأطفال في البلدان المنخفضة والمتوسطة الدخل. تشمل الصفوف الدقة التشخيصية الإجمالية، ونسبة النتائج غير الحاسمة، والأداء لدى الأطفال المصابين بفيروس العوز المناعي البشري ولدى الأطفال دون الخامسة، بحسب الاختبار؛ وتعرض الأعمدة عدد المشاركين والحساسية والنوعية المجمعتين أو معدلات النتائج غير الحاسمة، ومدلول النتائج عند معدل انتشار 10% و30%، وجودة البيّنات.",
        "zh": "GRADE结果摘要表，比较γ干扰素释放试验（T-SPOT、QFT-G/QFT-GIT）与结核菌素皮肤试验在中低收入国家诊断儿童活动性结核的表现。各行按检测方法列出总体诊断准确性、不确定结果比例、在感染艾滋病毒儿童和5岁以下儿童中的表现；各列为参与者人数、合并敏感性/特异性或不确定结果率、在患病率10%和30%时结果的含义以及证据质量。",
        "es": "Resumen de resultados GRADE sobre los IGRA (T-SPOT, QFT-G/QFT-GIT) frente a la PCT para diagnosticar la tuberculosis activa en niños en países de ingresos bajos y medianos. Las filas abarcan la exactitud diagnóstica global, la proporción de resultados indeterminados y el desempeño en niños con infección por el VIH y en menores de 5 años, por prueba; las columnas indican los participantes, la sensibilidad/especificidad combinadas o las tasas de resultados indeterminados, su significado con una prevalencia del 10% y del 30%, y la calidad de la evidencia.",
        "fr": "Synthèse des résultats GRADE sur les tests IGRA (T-SPOT, QFT-G/QFT-GIT) comparés à l’IDR pour le diagnostic de la tuberculose active chez l’enfant dans les pays à revenu faible ou intermédiaire. Les lignes couvrent l’exactitude diagnostique globale, la proportion de résultats indéterminés et la performance chez l’enfant infecté par le VIH et chez l’enfant de moins de 5 ans, par test ; les colonnes donnent les participants, la sensibilité/spécificité poolées ou les taux d’indéterminés, leur signification pour une prévalence de 10 % et de 30 %, et la qualité des données.",
        "ru": "Сводка результатов GRADE по тестам IGRA (T-SPOT, QFT-G/QFT-GIT) в сравнении с ТКП для диагностики активного туберкулеза у детей в странах с низким и средним уровнем дохода. Строки охватывают общую диагностическую точность, долю неопределенных результатов и эффективность у ВИЧ-инфицированных детей и детей до 5 лет по каждому тесту; столбцы — число участников, объединенные чувствительность/специфичность или долю неопределенных результатов, их значение при распространенности 10% и 30% и качество доказательств."
      },
      "csv": "tables/table-6.csv"
    },
    {
      "label": "Table 7",
      "caption": "Table 7. GRADE Evidence Profile: The role of IGRAs in the diagnosis of latent tuberculosis infection in HIV-infected individuals in low- and middle-income countries",
      "pages": [
        47,
        48
      ],
      "columns": [
        {
          "titles": "No of Participants (Studies)"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Limitations"
        },
        {
          "titles": "Indirectness"
        },
        {
          "titles": "Inconsistency"
        },
        {
          "titles": "Imprecision"
        },
        {
          "titles": "Publication bias"
        },
        {
          "titles": "Quality of evidence (GRADE)1"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "A. Outcome: Predictive value of IGRAs for active TB",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1100 (3) B1 LMIC: 306 (1)",
          "Prospective cohort",
          "Serious B2 (-1)",
          "Serious B3 (-1)",
          "None B4",
          "Serious B5 (-1)",
          "Likely B6",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "B. Outcome: Sensitivity for active TB (as a surrogate reference standard for LTBI)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1523 (18) D1 LMIC: 1056 (16)",
          "Mainly cross-sectional",
          "No serious limitations D2",
          "Serious D3 (-1)",
          "Very Serious D4 (-2)",
          "Serious D5 (-1)",
          "Likely D6",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "C. Outcome: Concordance with TST",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "2158 (15) E1 LMIC: 401 (5)",
          "Cross-sectional",
          "No serious limitations E2",
          "Very Serious E3 (-2)",
          "Serious E4 (-1)",
          "None E5 (-1)",
          "Likely E6",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ]
      ],
      "notes": "Footnotes * 1Quality of evidence was rated as high (no points subtracted), moderate (1 point subtracted), low (2 points subtracted), or very low (>2 points subtracted) based on five criteria: study limitations, indirectness of evidence, inconsistency in results across studies, imprecision in summary estimates, and likelihood of publication bias. For each outcome, the quality of evidence started at high when there were randomized controlled trials or high quality observational studies (cross-sectional or cohort studies enrolling patients with diagnostic uncertainty) and at moderate when these types of studies were absent. One point was subtracted when there was a serious issue identified or two points when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. B1 Three longitudinal studies that evaluated the ability of IGRAs to predict future development of active TB were identified. Two were conducted in high income countries (Austria and UK) and one in a low/middle income country (Cambodia). B2 Based on the Newcastle-Ottawa scale, the study samples were considered to be representative. However, only one study had an adequate duration of follow-up (≥1 year), all three studies scored poorly on outcome assessment did not adequately rule-out active TB at baseline or did not adequately evaluate all participants for active TB during follow-up, and all three studies had very few incident TB cases. B3 Two studies were carried out in high income countries; hence the findings may not be generalizable to low/middle income countries. B4 All three studies found that the risk of active TB was higher in IGRA positive compared to IGRA negative patients; but risk of progression to active TB was low in all groups. B5 The number of incident TB cases was small in all studies, leading to wide confidence intervals for risk estimates. In the two studies that reported cumulative incidence of TB, the difference in cumulative incidence of TB between IGRA positive and IGRA negative persons was not statistically significant. B6 Data included in the review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias could not be ruled out. Some degree of publication bias was assumed likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (despite an attempt to be comprehensive and include unpublished studies); 2) there are anecdotal examples of unpublished negative studies on IGRAs; and 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. However, we did not deduct points for this factor. D1 18 studies were identified: 9 evaluated TSPOT and 9 evaluated QFT-GIT. D2 Study limitations were evaluated using the QUADAS tool. 12 (67%) studies did not enroll a representative spectrum of patients (ambulatory HIV-infected patients suspected of having active TB). The majority of studies satisfied the remaining QUADAS criteria assessed. D3 16 (89%) studies were conducted in low/middle income countries. However, sensitivity for active TB may not reflect performance for LTBI and diagnostic accuracy is only a surrogate for patient-important outcomes. D4 There was significant heterogeneity in sensitivity estimates for both TSPOT (range 54-100%, I2 73%, p<0.002) and QFT-GIT (range 20-92%, I2 78%, p<0.001) in low/middle income countries. D5 The 95% confidence interval for pooled sensitivity was wide for both TSPOT (72%, 95% CI 62-81%) and QFT-GIT (61%, 47-75%) in low/middle income countries. D6 Data included in our review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias could not be ruled out. However, no points were deducted as additional negative studies were unlikely to bias the principal finding (sub-optimal IGRA sensitivity).. E1 15 studies were identified: 9 evaluated TSPOT and 6 evaluated QFT-GIT. E2 Study limitations were evaluated using the QUADAS scale. A majority of studies satisfied all QUADAS criteria assessed. E3 Only 5 of 9 studies for TSPOT and 1 of 6 studies for QFT-GIT were conducted in low/middle income countries. In addition, concordance between IGRAs and TST is a poor surrogate for patient-important outcomes. E4 Among studies conducted in low/middle income countries, there was significant heterogeneity in estimates of percent concordance between IGRA and TST for TSPOT (range 70-90%, I2 63%, p=0.04). There was only 1 study of QFT-GIT (concordance 91%). E5 The 95% confidence interval for pooled concordance was within +/10% in most sub-groups. E6 Data included in the review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias could be ruled out. Some degree of publication bias was assumed likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (despite an attempt to be comprehensive and include unpublished studies); 2) there are anecdotal examples of unpublished negative studies on IGRAs; and 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. However, no points were deducted for this factor. [Batch job pointed to p29 (list of tables); table is on p47, footnotes continue on p48.]",
      "narratives": {
        "en": "GRADE evidence profile on the role of IGRAs in diagnosing latent TB infection in people living with HIV in low- and middle-income countries. Three outcomes (predictive value for active TB, sensitivity for active TB as a surrogate for LTBI, and concordance with TST) are rated for study design, limitations, indirectness, inconsistency, imprecision, publication bias, quality of evidence and importance, with participant numbers overall and from LMIC.",
        "ar": "ملف بيّنات وفق منهجية GRADE بشأن دور مقايسات إطلاق الإنترفيرون غاما في تشخيص العدوى الكامنة بالسل لدى المصابين بفيروس العوز المناعي البشري في البلدان المنخفضة والمتوسطة الدخل. وتُقيَّم ثلاث حصائل (القيمة التنبؤية للسل النشط، والحساسية للسل النشط كبديل عن العدوى الكامنة، والتوافق مع اختبار التوبركولين الجلدي) من حيث تصميم الدراسة والقيود وعدم المباشرة وعدم الاتساق وعدم الدقة وتحيز النشر وجودة البيّنات والأهمية، مع عدد المشاركين إجمالاً ومن هذه البلدان.",
        "zh": "GRADE证据概况表，涉及γ干扰素释放试验在中低收入国家艾滋病毒感染者结核潜伏感染诊断中的作用。三项结局（对活动性结核的预测价值、作为潜伏感染替代指标的活动性结核敏感性、与结核菌素皮肤试验的一致性）按研究设计、局限性、间接性、不一致性、不精确性、发表偏倚、证据质量和重要性评价，并列出总参与者人数和中低收入国家参与者人数。",
        "es": "Perfil de evidencia GRADE sobre la función de los IGRA en el diagnóstico de la infección tuberculosa latente en personas con el VIH en países de ingresos bajos y medianos. Tres resultados (valor predictivo de tuberculosis activa, sensibilidad para la tuberculosis activa como sustituto de la infección latente y concordancia con la PCT) se califican por diseño, limitaciones, carácter indirecto, incoherencia, imprecisión, sesgo de publicación, calidad e importancia, con el número de participantes total y de estos países.",
        "fr": "Profil de données probantes GRADE sur le rôle des tests IGRA dans le diagnostic de l’infection tuberculeuse latente chez les personnes vivant avec le VIH dans les pays à revenu faible ou intermédiaire. Trois critères (valeur prédictive de tuberculose active, sensibilité pour la tuberculose active comme substitut de l’infection latente, concordance avec l’IDR) sont évalués selon le plan d’étude, les limites, le caractère indirect, l’incohérence, l’imprécision, le biais de publication, la qualité et l’importance, avec le nombre de participants total et dans ces pays.",
        "ru": "Профиль доказательств GRADE о роли тестов IGRA в диагностике латентной туберкулезной инфекции у людей с ВИЧ в странах с низким и средним уровнем дохода. Три исхода (прогностическая ценность в отношении активного туберкулеза, чувствительность при активном туберкулезе как суррогат ЛТИ и согласованность с ТКП) оцениваются по дизайну, ограничениям, косвенности, несогласованности, неточности, публикационной ошибке, качеству и значимости, с числом участников всего и из этих стран."
      },
      "csv": "tables/table-7.csv"
    },
    {
      "label": "Table 8",
      "caption": "Table 8. GRADE Summary of Findings – Role of IGRAs in the diagnosis of latent tuberculosis infection in HIV-infected individuals in low- and middle-income countries",
      "pages": [
        49
      ],
      "columns": [
        {
          "titles": "Outcome"
        },
        {
          "titles": "N"
        },
        {
          "titles": "Principal Findings"
        },
        {
          "titles": "What do these findings mean?"
        },
        {
          "titles": "Quality of Evidence"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "Predictive value for active TB",
          "1100 (3 studies)",
          "1) TSPOT: Cumulative incidence of active TB higher in IGRA+ compared to IGRA- individuals, but difference not statistically significant (10% vs. 0%, risk difference 10%, 95% CI -3% to +23%). 2) QGT-GIT: Cumulative incidence of active TB higher in IGRA+ compared to IGRA- individuals, but difference not statistically significant (8% vs. 0%, risk difference 8%, 95% CI -0.7% to 17%).",
          "IGRA+ individuals may have a higher risk of progression to active TB than IGRA- individuals, but the risk of progression is low in both groups.",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "Sensitivity for active TB (a surrogate reference standard for LTBI)",
          "1523 (18 studies)",
          "1) TSPOT: Pooled sensitivity 72% (95% CI 62-81%); TSPOT more sensitive than TST in 1 study, less sensitive in 1 study, and as sensitive in 1 study. 2) QFT-GIT: Pooled sensitivity was 61% (95% CI 47-75%). Compared to TST, QFT-GIT more sensitive in 1 study and less sensitive in 1 study.",
          "In low- and middle-income countries, IGRAs have suboptimal sensitivity for active TB and do not consistently have higher sensitivity than TST.",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "Concordance with TST",
          "1822 (14 studies)",
          "1) TSPOT: Pooled concordance 77% (95% CI 67-88%). 2) QFT-GIT: 1 study; concordance 91%.",
          "In low- and middle-income countries, IGRAs have moderate concordance with TST.",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ]
      ],
      "notes": "Header block above the table: Review question: What is the role of IGRAs in the diagnosis of latent tuberculosis infection (LTBI) in HIV-infected individuals? Patients/population: HIV-infected active TB suspects or HIV-infected persons being screened for LTBI; all ages, all countries (data specific to low- and middle-income countries presented when available). Setting: Outpatients and inpatients. Index test: QuantiFERON-Gold In-tube [QFT-GIT] and T-SPOT.TB [TSPOT]. Importance: The performance IGRAs in diagnosing LTBI among HIV-infected individuals is uncertain; it is unclear if IGRAs should be used to identify HIV-infected persons with LTBI who could benefit from preventive therapy. Reference standard: See hierarchy of reference standards (Fig 1). Studies: Randomized controlled trials, observational studies (cohort, cross-sectional, case-control). [Batch job pointed to p29 (list of tables); table is on p49.]",
      "narratives": {
        "en": "GRADE summary of findings on IGRAs for diagnosing latent TB infection in people living with HIV. Rows are three outcomes (predictive value for active TB, sensitivity for active TB as a surrogate for LTBI, concordance with TST); columns give the number of participants and studies, principal findings for TSPOT and QFT-GIT, what they mean, quality of evidence and importance.",
        "ar": "ملخص نتائج وفق منهجية GRADE بشأن مقايسات إطلاق الإنترفيرون غاما لتشخيص العدوى الكامنة بالسل لدى المصابين بفيروس العوز المناعي البشري. تمثل الصفوف ثلاث حصائل (القيمة التنبؤية للسل النشط، والحساسية للسل النشط كبديل، والتوافق مع اختبار التوبركولين الجلدي)، وتعرض الأعمدة عدد المشاركين والدراسات والنتائج الرئيسية لاختباري TSPOT وQFT-GIT ومدلولها وجودة البيّنات والأهمية.",
        "zh": "GRADE结果摘要表，涉及γ干扰素释放试验诊断艾滋病毒感染者结核潜伏感染。各行为三项结局（对活动性结核的预测价值、作为替代指标的活动性结核敏感性、与结核菌素皮肤试验的一致性）；各列为参与者和研究数、TSPOT和QFT-GIT的主要结果、其含义、证据质量和重要性。",
        "es": "Resumen de resultados GRADE sobre los IGRA para diagnosticar la infección tuberculosa latente en personas con el VIH. Las filas son tres resultados (valor predictivo de tuberculosis activa, sensibilidad para la tuberculosis activa como sustituto y concordancia con la PCT); las columnas indican el número de participantes y estudios, los hallazgos principales para TSPOT y QFT-GIT, su significado, la calidad de la evidencia y la importancia.",
        "fr": "Synthèse des résultats GRADE sur les tests IGRA pour le diagnostic de l’infection tuberculeuse latente chez les personnes vivant avec le VIH. Les lignes sont trois critères (valeur prédictive de tuberculose active, sensibilité pour la tuberculose active comme substitut, concordance avec l’IDR) ; les colonnes donnent le nombre de participants et d’études, les principaux résultats pour TSPOT et QFT-GIT, leur signification, la qualité des données et l’importance.",
        "ru": "Сводка результатов GRADE по тестам IGRA для диагностики латентной туберкулезной инфекции у людей с ВИЧ. Строки — три исхода (прогностическая ценность в отношении активного туберкулеза, чувствительность при активном туберкулезе как суррогат, согласованность с ТКП); столбцы — число участников и исследований, основные результаты для TSPOT и QFT-GIT, их значение, качество доказательств и значимость."
      },
      "csv": "tables/table-8.csv"
    },
    {
      "label": "Table 9",
      "caption": "Table 9. GRADE Evidence Profile: IGRAs for tuberculosis screening of healthcare workers in low- and middle-income countries",
      "pages": [
        50,
        51,
        52
      ],
      "columns": [
        {
          "titles": "No of participants (studies)"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Limitations"
        },
        {
          "titles": "Indirectness"
        },
        {
          "titles": "Inconsistency"
        },
        {
          "titles": "Imprecision"
        },
        {
          "titles": "Publication bias"
        },
        {
          "titles": "Quality of evidence (GRADE)1"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "A. Efficacy of preventive therapy based on IGRA test results",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "B. Predictive value of IGRA for active TB",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "C. Outcome: Correlation of IGRA results with occupational TB exposure",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "991 (2) A1",
          "Cross-sectional",
          "No serious limitations A2",
          "No serious Indirectness A3",
          "Serious A4 (-1)",
          "Serious A5 (-1)",
          "Likely A6",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ],
        [
          "D. Outcome: Correlation between IGRA conversions and occupational TB exposure",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "E. Outcome: Sensitivity for active TB (as a surrogate reference standard for LTBI)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No Studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Important (4-6)"
        ],
        [
          "F. Outcome: Concordance between IGRAs and TST (cross-sectional)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "1,357 (4) B1",
          "Cross-sectional",
          "No serious limitations B2",
          "Serious B3 (-1)",
          "Serious B4 (-1)",
          "Serious B5 (-1)",
          "Likely B6",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "G. Outcome: concordance between IGRA and TST conversions (longitudinal)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "216 (1) C1",
          "Longitudinal",
          "No serious limitations C2",
          "Serious C3 (-1)",
          "No serious inconsistency C4",
          "Very Serious C5 (-2)",
          "Likely C6",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ]
      ],
      "notes": "Footnotes: 1Quality of evidence was rated as high (no points subtracted), moderate (1 point subtracted), low (2 points subtracted), or very low (>2 points subtracted) based on five criteria: imitations, indirectness, inconsistency, imprecision, and publication bias. For each outcome, the quality of evidence started at high when there were randomized controlled trials or high quality observational studies (cross-sectional or cohort studies with diagnostic uncertainty and direct comparison of test results with culture) and at moderate when these types of studies were absent. One point was subtracted when there was a serious issue identified or two points when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. A1 2 studies were identified evaluating an association between test positivity and occupational exposure to TB. These studies compared only QFT and the TST. A2 Study limitations were assessed using select quality indicators. Studies satisfied majority of selected quality indicators. A3 Some indirectness in the choice of reference standard was recognised although the studies were not downgraded for indirectness. A4 Two studies evaluated the association between 5 variables of occupational exposure to TB and test positivity, estimates ranged from OR=1.28-5.09. A5 Only 50% of estimates of association of test positivity and exposure reached statistical significance, 95% confidence intervals ranged from: 0.68-9.33. With only two studies, imprecision may be a concern. A6 Data included in this review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias could not be ruled out. Although no points were deducted, some degree of publication bias was considered likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (despite an attempt to be comprehensive and include unpublished studies); 2) there are anecdotal examples of unpublished negative studies on IGRAs; 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. B1 4 cross-sectional studies were identified: 3 evaluated a previous version of the QFT, 1 study evaluated only the T-SPOT.TB. B2 Study limitations were assessed using select quality indicators as the QUADAS scale was not appropriate for concordance studies. Majority of studies satisfied selected quality indicators. B3 Concordance between IGRAs and the TST is a poor surrogate for patient important outcomes. B4 Among studies conducted in low- and middle-income countries, there was moderate heterogeneity in estimates of percent agreement between TST and IGRAs (Range: 50-81%). B5 Due to heterogeneity in effect estimates we could not pool concordance. However, confidence intervals for estimates of concordance for individual studies were wide, and with only 4 studies, imprecision may be a concern B6 Data included in the review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias could not be ruled out. Although no points were deducted, some degree of publication bias was considered likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (despite an attempt to be comprehensive and include unpublished studies); 2) there are anecdotal examples of unpublished negative studies on IGRAs; 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. C1 1 longitudinal study was included which assessed concordance between TST and IGRA conversions, using the QFT test. C2 Study limitations were assessed using select quality indicators as the QUADAS scale was not appropriate for concordance studies. Both studies satisfied the majority of selected quality indicators. C3 This study was conducted in a low middle income country. Concordance between IGRA and the TST conversions is a poor surrogate for patient important outcomes, and may not be an appropriate reference standard. C4 This study estimated fair concordance between QFT and TST conversions (96%). C5 Only 1 study was identified with a small number of participants (n=216). C6 Data included in this review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias could not be ruled out. Although no points were deducted, some degree of publication bias was considered likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (despite an attempt to be comprehensive and include unpublished studies); 2) there are anecdotal examples of unpublished negative studies on IGRAs; 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. [Batch job pointed to p29 (list of tables); table runs pp. 50-51, footnotes to p52.]",
      "narratives": {
        "en": "GRADE evidence profile on IGRAs for TB screening of health-care workers in low- and middle-income countries. Seven outcomes (efficacy of preventive therapy based on IGRA results, predictive value, correlation of IGRA results and conversions with occupational exposure, sensitivity for active TB, and cross-sectional and longitudinal concordance with TST) are listed; where studies exist, they are rated for design, limitations, indirectness, inconsistency, imprecision, publication bias, quality and importance.",
        "ar": "ملف بيّنات وفق منهجية GRADE بشأن استخدام مقايسات إطلاق الإنترفيرون غاما في فحص العاملين الصحيين للكشف عن السل في البلدان المنخفضة والمتوسطة الدخل. ويسرد سبع حصائل (فعالية العلاج الوقائي استناداً إلى نتائج المقايسات، والقيمة التنبؤية، وارتباط النتائج والتحولات بالتعرض المهني، والحساسية للسل النشط، والتوافق المقطعي والطولي مع اختبار التوبركولين الجلدي)، وحيثما توجد دراسات تُقيَّم من حيث التصميم والقيود وعدم المباشرة وعدم الاتساق وعدم الدقة وتحيز النشر والجودة والأهمية.",
        "zh": "GRADE证据概况表，涉及在中低收入国家使用γ干扰素释放试验对卫生工作者进行结核筛查。列出七项结局（基于IGRA结果的预防性治疗效果、预测价值、IGRA结果及转阳与职业暴露的相关性、活动性结核敏感性，以及与结核菌素皮肤试验的横断面和纵向一致性）；有研究的结局按设计、局限性、间接性、不一致性、不精确性、发表偏倚、质量和重要性评价。",
        "es": "Perfil de evidencia GRADE sobre los IGRA para el cribado de la tuberculosis en trabajadores de la salud en países de ingresos bajos y medianos. Se enumeran siete resultados (eficacia del tratamiento preventivo según los IGRA, valor predictivo, correlación de los resultados y las conversiones con la exposición ocupacional, sensibilidad para la tuberculosis activa y concordancia transversal y longitudinal con la PCT); cuando hay estudios, se califican por diseño, limitaciones, carácter indirecto, incoherencia, imprecisión, sesgo de publicación, calidad e importancia.",
        "fr": "Profil de données probantes GRADE sur les tests IGRA pour le dépistage de la tuberculose chez les agents de santé dans les pays à revenu faible ou intermédiaire. Sept critères sont énumérés (efficacité du traitement préventif fondé sur les IGRA, valeur prédictive, corrélation des résultats et des conversions avec l’exposition professionnelle, sensibilité pour la tuberculose active, concordance transversale et longitudinale avec l’IDR) ; lorsqu’il existe des études, ils sont évalués selon le plan, les limites, le caractère indirect, l’incohérence, l’imprécision, le biais de publication, la qualité et l’importance.",
        "ru": "Профиль доказательств GRADE о применении тестов IGRA для скрининга работников здравоохранения на туберкулез в странах с низким и средним уровнем дохода. Перечислены семь исходов (эффективность профилактического лечения по результатам IGRA, прогностическая ценность, связь результатов и конверсий с профессиональным контактом, чувствительность при активном туберкулезе, поперечная и продольная согласованность с ТКП); при наличии исследований они оцениваются по дизайну, ограничениям, косвенности, несогласованности, неточности, публикационной ошибке, качеству и значимости."
      },
      "csv": "tables/table-9.csv"
    },
    {
      "label": "Table 10",
      "caption": "Table 10. GRADE Summary of Findings – IGRAs for tuberculosis screening of healthcare workers in low- and middle-income countries",
      "pages": [
        53,
        54
      ],
      "columns": [
        {
          "titles": "Outcome"
        },
        {
          "titles": "No. Partici-pants"
        },
        {
          "titles": "Principal Findings"
        },
        {
          "titles": "What do these findings mean?"
        },
        {
          "titles": "Quality of Evidence"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "Efficacy of preventive therapy based on IGRA test results",
          "No Studies in HCWs",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "Predictive value of IGRA for active TB",
          "No Studies in HCWs",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "Correlation between IGRA positivity and occupational TB exposure",
          "991 (2 studies)",
          "1) T-SPOT.TB: No studies evaluated T-SPOT.TB 2) QFT: All 5 comparisons gave positive estimates for the association between test positivity and occupational exposure (OR=1.28-4.15), 3/5 reached statistical significance. 3) TST: All 5 comparisons gave positive effect estimates (OR=1.33-5.09), 2/5 reached statistical significance.",
          "Data were limited on T-SPOT.TB and from low and middle income settings. Occupational exposure was associated with positivity for both tests, although this was not always significant. There is no strong evidence that IGRAs are more strongly correlated with occupational TB exposure than TST.",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ],
        [
          "Correlation between IGRA conversions and occupational TB exposure",
          "No Studies in HCWs",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "Sensitivity for active TB (as a surrogate reference standard for LTBI)",
          "No Studies in HCWs",
          "",
          "",
          "",
          "Important (4-6)"
        ],
        [
          "Concordance between TST and IGRAs",
          "1,357 (4 studies)",
          "In low and middle income studies, agreement between IGRA and TST results ranged from 50.2%-81.4%. While IGRA consistently estimated a lower rate, this difference was significant in only 2/4 cases.",
          "Concordance was fair to poor in low and middle income settings. Both tests provide similar estimates of prevalence in low and middle income countries.",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "Concordance between IGRA and TST conversions",
          "216 (1 study)",
          "This study found 96% agreement between test conversions (QFT & TST).",
          "IGRA and TST conversions show moderate concordance. Data are limited in all settings.",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ]
      ],
      "notes": "Header block above the table: Review question: What is the role of IGRAs in the diagnosis of latent tuberculosis infection (LTBI) in health care workers (HCWs)? Study Population: Healthcare workers being screened for LTBI, all ages, from middle and low income countries. Setting: Occupational screening of HCWs for LTBI. Index test: QuantiFERON-Gold or Gold In-tube (QFT) and T-SPOT.TB. Importance: The performance of IGRAs in diagnosing LTBI in HCWs is uncertain, it is unclear if IGRAs should be used in HCWs to identify those who could benefit from preventive therapy. In particular, it is unclear whether IGRA conversions identify those who could benefit from preventive therapy. Reference standard: See hierarchy of reference standards (Figure 1). Studies: Observational studies (longitudinal cohort, cross-sectional, case-control). [Batch job pointed to p29 (list of tables); table is on pp. 53-54.]",
      "narratives": {
        "en": "GRADE summary of findings on IGRAs for TB screening of health-care workers in low- and middle-income countries. Rows are seven outcomes, four of which have no studies in health-care workers; for the others (correlation with occupational exposure, concordance with TST, concordance of conversions) columns give participants, principal findings, their meaning, quality of evidence and importance.",
        "ar": "ملخص نتائج وفق منهجية GRADE بشأن مقايسات إطلاق الإنترفيرون غاما لفحص العاملين الصحيين للكشف عن السل في البلدان المنخفضة والمتوسطة الدخل. تمثل الصفوف سبع حصائل، لا توجد دراسات لدى العاملين الصحيين بشأن أربع منها؛ وبالنسبة للحصائل الأخرى (الارتباط بالتعرض المهني، والتوافق مع اختبار التوبركولين الجلدي، وتوافق التحولات) تعرض الأعمدة عدد المشاركين والنتائج الرئيسية ومدلولها وجودة البيّنات والأهمية.",
        "zh": "GRADE结果摘要表，涉及在中低收入国家使用γ干扰素释放试验对卫生工作者进行结核筛查。各行为七项结局，其中四项在卫生工作者中无研究；其余结局（与职业暴露的相关性、与结核菌素皮肤试验的一致性、转阳一致性）各列给出参与者人数、主要结果、其含义、证据质量和重要性。",
        "es": "Resumen de resultados GRADE sobre los IGRA para el cribado de la tuberculosis en trabajadores de la salud en países de ingresos bajos y medianos. Las filas son siete resultados, cuatro de ellos sin estudios en trabajadores de la salud; para los demás (correlación con la exposición ocupacional, concordancia con la PCT y concordancia de las conversiones) las columnas indican participantes, hallazgos principales, su significado, calidad de la evidencia e importancia.",
        "fr": "Synthèse des résultats GRADE sur les tests IGRA pour le dépistage de la tuberculose chez les agents de santé dans les pays à revenu faible ou intermédiaire. Les lignes sont sept critères, dont quatre sans étude chez les agents de santé ; pour les autres (corrélation avec l’exposition professionnelle, concordance avec l’IDR, concordance des conversions), les colonnes donnent les participants, les principaux résultats, leur signification, la qualité des données et l’importance.",
        "ru": "Сводка результатов GRADE по тестам IGRA для скрининга работников здравоохранения на туберкулез в странах с низким и средним уровнем дохода. Строки — семь исходов, по четырем из которых исследований среди медработников нет; для остальных (связь с профессиональным контактом, согласованность с ТКП, согласованность конверсий) в столбцах указаны число участников, основные результаты, их значение, качество доказательств и значимость."
      },
      "csv": "tables/table-10.csv"
    },
    {
      "label": "Table 11",
      "caption": "Table 11. GRADE Evidence Profile: Performance of IGRAs for the diagnosis of LTBI in contacts of active TB in low-and middle-income countries",
      "pages": [
        55,
        56,
        57
      ],
      "columns": [
        {
          "titles": "No of Participants (Studies)"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Limitations"
        },
        {
          "titles": "Indirectness"
        },
        {
          "titles": "Inconsistency"
        },
        {
          "titles": "Imprecision"
        },
        {
          "titles": "Publication bias"
        },
        {
          "titles": "Quality of evidence (GRADE)1"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "A. Efficacy of preventive therapy based on IGRA test results",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No Studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "B. Predictive value of IGRA for active TB",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "9 studies:",
          "Covered in",
          "Predictive SR:",
          "Rangaka et al",
          "",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "C. Outcome: Correlation between IGRAs and different gradients of TB exposure (ordinal, continuous, etc.)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "3,868 (9) A1",
          "Cross-sectional",
          "Serious A2 (-1)",
          "No Serious indirectness A3",
          "Serious A4 (-1)",
          "No serious imprecision A5",
          "Likely A6",
          "Low ⊕⊕○○",
          "Critical (7-9)"
        ],
        [
          "D. Outcome: Correlation between IGRAs and TB exposure as a dichotomous variable",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "3,145 (6) B1",
          "Mainly cross-sectional",
          "Serious B2 (-1)",
          "No Serious indirectness B3",
          "Serious B4 (-1)",
          "Serious B5 (-1)",
          "Likely B6",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "E. Outcome: Correlation between IGRA conversions and TB exposure",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "309 (2) C1",
          "Longitudinal",
          "Serious C2 (-1)",
          "No Serious indirectness C3",
          "Very Serious C4 (-2)",
          "Serious C5 (-1)",
          "Likely C6",
          "Very Low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "F. Outcome: Sensitivity for active TB (as a surrogate reference standard for LTBI)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No Studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Important (4-6)"
        ],
        [
          "G. Outcome: Concordance with tuberculin skin test (TST)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "5,080 (16) D1",
          "Mainly cross-sectional",
          "Serious D2 (-1)",
          "Very Serious D3 (-2)",
          "Very Serious D4 (-2)",
          "Serious D5 (-1)",
          "Likely D6",
          "Very Low ⊕○○○",
          "Important (4-6)"
        ]
      ],
      "notes": "Footnotes: 1Quality of evidence was rated as high (no points subtracted), moderate (1 point subtracted), low (2 points subtracted), or very low (>2 points subtracted) based on five criteria: imitations, indirectness, inconsistency, imprecision, and publication bias. For each outcome, the quality of evidence started at high when there were randomized controlled trials or high quality observational studies (cross-sectional or cohort studies with diagnostic uncertainty and direct comparison of test results with culture) and at moderate when these types of studies were absent. One point was subtracted when there was a serious issue identified or two points when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. A1 9 studies were included: 1 study evaluated both T-SPOT.TB and QFT-GIT, 2 studies evaluated T-SPOT.TB, the 6 remaining studies evaluated QFT-GIT(n=5) or QFT-G(n=1). A22 out of 9 studies were unpublished and quality indicators could not be assessed; remaining study populations were considered to be representative, however, only 1 of the remaining 7 studies reported that assessment of test results was performed blinded to other test results. Only 2/7 reported the blood draw had been performed prior to the TST. A333% (3/9) studies were done in low-income settings and the remaining 6 studies were done in middle-income settings. Some indirectness in the choice of reference standard was observed. A4 Serious heterogeneity in characterization of exposure gradient (some based on index case’s smear status, some based on sleeping proximity, etc.) and in estimated effect. A5 Majority of studies had 200-300 participants, smallest study n=120. Estimated 95%CIs were relatively tight. A6 Data included in the review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias could not be ruled out. Although no points were deducted, it was assumed that some degree of publication bias is likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (although an attempt was made to include unpublished studies, despite not being comprehensive); 2) there are anecdotal examples of unpublished negative studies on IGRAs; 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. B16 studies were identified: 1 study evaluated both T-SPOT.TB and QFT-G, while 1 study evaluated T-SPOT.TB. The remaining 4 studies all evaluated QFT-GIT. B2Only the 4 published studies could be assessed for quality, 50% reported on timing of blood draw prior to TST, 50% reported blinding had been done for assessment of test results and 50% reported industry involvement. B3All studies, except one done in low-income setting were done in upper-middle income settings. Some indirectness in the choice of reference standard was noted. B4 Serious heterogeneity in characterization of exposure gradient (some based on index case’s smear status, some based on sleeping proximity, etc.) and in estimated effect. B5 All but one large study (n=2211) had between 82-301 participants. Studies estimated wide 95%CI, and majority were not significant. B6 Data included in the review did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias could not be ruled out. Although no points were deducted, it was assumed some degree of publication bias was likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (although an attempt was made to include unpublished studies, despite not being comprehensive); 2) there are anecdotal examples of unpublished negative studies on IGRAs; 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. C1 2 studies were included; both studies evaluated the QFT, one study using the QFT-GIT and the other the QFT-G. C21 study was unpublished and hence not suitable for quality assessment; the other study was a longitudinal study that followed HCWs after a nosocomial infection. Population was representative, blood draw was done prior to TST, and there was no industry involvement, however, blinding was not reported. C3 Both studies were done in Upper middle income settings, however one was a nosocomial outbreak involving health care workers and may not be generalizeable to other contact settings including household contacts, especially in low income settings. While we did not downgrade for reference standard, we acknowledge there is some indirectness in the choice of reference standard. C4 Serious heterogeneity between estimated ORs for exposure and conversions, one study shows a positive association between conversions and exposure, while the other shows a significant protective effect of exposure for conversions. C595% CIs are tight and significant for the large unpublished (n=2211), however, CIs range from 0.18-21.12 and 0.69-122.38 for the smaller hospital outbreak study (n=39) C6 Data included did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias cannot be ruled out. Although we did not deduct points, we assumed some degree of publication bias is likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (although we made an attempt to include unpublished studies, our attempt was not comprehensive); 2) there are anecdotal examples of unpublished negative studies on IGRAs; 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. D12 studies included both IGRAs, 3 studies evaluated only T-SPOT.TB, while the rest evaluated a version of the QFT. D211/14 studies did not report on whether personnel assessing test results had been blinded to previous test results or reference standard and 5/14 studies reported industry involvement. D3Studies were conducted in low and middle income settings. TB exposure gradient does not necessarily classify the target condition (LTBI) correctly. D447% of studies showed moderate agreement, while 26.5% showed poor agreement and 26.5% fair agreement. In 68% of comparisons, TST estimated a higher prevalence while in the remaining 32% IGRAs estimated a higher prevalence of LTBI. D5Due to heterogeneity in effect estimates concordance could not be pooled. However, effects estimated for individual studies were frequently not significant. D6 Data included did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias cannot be ruled out. Although points were not deducted, a degree of publication bias is likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (although we made an attempt to include unpublished studies, our attempt was not comprehensive); 2) there are anecdotal examples of unpublished negative studies on IGRAs; 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. [Batch job pointed to p29 (list of tables); table is on p55, footnotes on pp. 56-57. Row 4 is printed as fragments across cells (\"9 studies: | Covered in | Predictive SR: | Rangaka et al\").]",
      "narratives": {
        "en": "GRADE evidence profile on the performance of IGRAs for diagnosing latent TB infection in contacts of active TB cases in low- and middle-income countries. Seven outcomes (efficacy of preventive therapy, predictive value, correlation with exposure gradients and with dichotomous exposure, correlation of conversions with exposure, sensitivity for active TB, concordance with TST) are rated where studies exist for design, limitations, indirectness, inconsistency, imprecision, publication bias, quality and importance.",
        "ar": "ملف بيّنات وفق منهجية GRADE بشأن أداء مقايسات إطلاق الإنترفيرون غاما في تشخيص العدوى الكامنة بالسل لدى مخالطي حالات السل النشط في البلدان المنخفضة والمتوسطة الدخل. وتُقيَّم سبع حصائل (فعالية العلاج الوقائي، والقيمة التنبؤية، والارتباط بتدرجات التعرض وبالتعرض الثنائي، وارتباط التحولات بالتعرض، والحساسية للسل النشط، والتوافق مع اختبار التوبركولين الجلدي) حيثما توجد دراسات، من حيث التصميم والقيود وعدم المباشرة وعدم الاتساق وعدم الدقة وتحيز النشر والجودة والأهمية.",
        "zh": "GRADE证据概况表，涉及γ干扰素释放试验在中低收入国家诊断活动性结核接触者结核潜伏感染的表现。七项结局（预防性治疗效果、预测价值、与暴露梯度及二分暴露的相关性、转阳与暴露的相关性、活动性结核敏感性、与结核菌素皮肤试验的一致性）在有研究时按设计、局限性、间接性、不一致性、不精确性、发表偏倚、质量和重要性评价。",
        "es": "Perfil de evidencia GRADE sobre el desempeño de los IGRA para diagnosticar la infección tuberculosa latente en contactos de casos de tuberculosis activa en países de ingresos bajos y medianos. Siete resultados (eficacia del tratamiento preventivo, valor predictivo, correlación con gradientes de exposición y con exposición dicotómica, correlación de las conversiones con la exposición, sensibilidad para la tuberculosis activa, concordancia con la PCT) se califican, cuando hay estudios, por diseño, limitaciones, carácter indirecto, incoherencia, imprecisión, sesgo de publicación, calidad e importancia.",
        "fr": "Profil de données probantes GRADE sur la performance des tests IGRA pour le diagnostic de l’infection tuberculeuse latente chez les contacts de cas de tuberculose active dans les pays à revenu faible ou intermédiaire. Sept critères (efficacité du traitement préventif, valeur prédictive, corrélation avec les gradients d’exposition et avec une exposition dichotomique, corrélation des conversions avec l’exposition, sensibilité pour la tuberculose active, concordance avec l’IDR) sont évalués, lorsqu’il existe des études, selon le plan, les limites, le caractère indirect, l’incohérence, l’imprécision, le biais de publication, la qualité et l’importance.",
        "ru": "Профиль доказательств GRADE об эффективности тестов IGRA для диагностики латентной туберкулезной инфекции у контактов больных активным туберкулезом в странах с низким и средним уровнем дохода. Семь исходов (эффективность профилактического лечения, прогностическая ценность, связь с градиентами контакта и с дихотомическим контактом, связь конверсий с контактом, чувствительность при активном туберкулезе, согласованность с ТКП) оцениваются при наличии исследований по дизайну, ограничениям, косвенности, несогласованности, неточности, публикационной ошибке, качеству и значимости."
      },
      "csv": "tables/table-11.csv"
    },
    {
      "label": "Table 12",
      "caption": "Table 12. GRADE Evidence Profile: Predictive value of commercial IGRA for incident active TB in low- and middle-Income countries",
      "pages": [
        58,
        59,
        60
      ],
      "columns": [
        {
          "titles": "No of Participants (Studies)"
        },
        {
          "titles": "Study design"
        },
        {
          "titles": "Limitations"
        },
        {
          "titles": "Indirectness"
        },
        {
          "titles": "Inconsistency"
        },
        {
          "titles": "Imprecision"
        },
        {
          "titles": "Publication Bias"
        },
        {
          "titles": "Quality of Evidence (GRADE)1"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "A. Outcome: Efficacy of preventive therapy based on IGRA results",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "B. Outcome: Prospective predictive value of IGRA for the development of active incident TB? (Do IGRA positive results have a stronger association with subsequent development of active TB compared to IGRA negative results?)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7,392 (3) B1",
          "Cohort studies",
          "Serious (-1) B2",
          "Serious (-1) B3",
          "No serious inconsistency B4",
          "Very Serious (-2) B5",
          "Likely 6",
          "Very low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "C. Outcome: Predictive value of IGRA for the development of active incident TB compared to the TST (Are IGRAs (positive vs. negative) have a stronger statistical association with subsequent active TB than the TST (positive vs. negative)?",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7,392 (3) C1",
          "Cohort studies",
          "Serious (-1) C2",
          "Serious (-1) C3",
          "No serious inconsistency C4",
          "Very Serious (-2) C5",
          "Likely C6",
          "Very low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "D. Outcome: Predictive value of IGRA for subsequent TB when IGRA are evaluated as part of a multivariable clinical algorithm for predicting TB (Additive value of IGRA)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Important (4-6)"
        ],
        [
          "E. Outcome: Quantitative IGRA levels and subsequent rates of TB",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "721 (1) E1",
          "Cohort of TB case-contacts",
          "Serious (-1) E2",
          "Serious (-1) E3",
          "Serious (-1) E4",
          "Very Serious (-2) E5",
          "Likely E6",
          "Very low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "F. Outcome: Immunological phenotypes of discordant-concordant TST/IGRA pairs and subsequent rates of TB",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "5,861 (2) F1",
          "Cohort studies",
          "Serious (-1) F2",
          "Serious (-1) F3",
          "Serious (-1) F4",
          "Very Serious (-2) F5",
          "Likely F6",
          "Very low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "G. Outcome: Sensitivity, Specificity, False positive rates etc for active TB (as surrogates of patient relevant outcomes)",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "7,392 (3) G1",
          "Cohort studies",
          "Serious (-1) G2",
          "Serious (-1) G3",
          "Serious (-1) G4",
          "Very Serious (-2) G5",
          "Likely G6",
          "Very low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "H. Outcome: Utility of repeated or serial IGRA results for predicting subsequent incident active TB",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          ""
        ],
        [
          "No studies",
          "",
          "",
          "",
          "",
          "",
          "",
          "",
          "Important (4-6)"
        ]
      ],
      "notes": "Footnotes 1 Quality of evidence was rated as high (no points subtracted), moderate (1 point subtracted), low (2 points subtracted), or very low (>2 points subtracted) based on five criteria: study limitations, indirectness of evidence, inconsistency in results across studies, imprecision in summary estimates, and likelihood of publication bias. For each outcome, the quality of evidence started at high when there were randomized controlled trials or high quality observational studies and at moderate when these types of studies were absent. We then subtracted one point when there was a serious issue identified or two points when there was a very serious issue identified in any of the criteria used to judge the quality of evidence. B1 3 studies were eligible and thus included in the analysis; 1 published (China) and 2 unpublished (Zambia and South Africa). (N refers to numbers that entered follow-up) B2 Based on the Newcastle-Ottawa scale, study samples were considered to be representative of specific groups of interest (i.e., silicosis patients (China), case-contacts (Zambia), adolescent school-goers) within the population and IGRA exposure groups were drawn from the same sample and therefore unlikely to introduce any bias. However, studies varied with regard to the comparability (adjustments made to effect measures) and outcome (ascertainment, losses to follow-up, reporting) components of the modified NOS. Lack of proper ascertainment of the TB outcome is considered to be the most serious of limitations. A point is deducted. B3 The results of the studies could be generalized for the specific country/region and for those specific groups of interest. However, the small number of studies warrants caution; a point is deducted for indirectness. B4 All 3 studies showed similar results and with very little heterogeneity in the pooled incidence rate ratio (I2=0%, p=0.912). No points were deducted. B5 The number of incident TB cases was small in all studies and the rates of TB fairly moderate; confidence intervals for relative risk estimates were wide (precision > +/- 20%). This is a very serious limitation. Two points are deducted. B6 Data included did not allow for formal assessment of publication bias using methods such as funnel plots or regression tests. Therefore, publication bias cannot be ruled out. Although no points were deducted, a degree of publication bias is likely because: 1) literature on IGRAs is rapidly exploding and currently unpublished studies may come out in future (although we made an attempt to include unpublished studies, our attempt was not comprehensive; we are aware of at least one unpublished study that was not assessed for this review); 2) there are anecdotal examples of unpublished negative studies on IGRAs; and 3) because a sizeable proportion of IGRA studies have some level of industry involvement or support, the risk of unpublished negative studies (or delayed publication of negative studies) is not trivial. C1 All three studies provided incidence rates of TB stratified by IGRA as well as TST status at baseline. (N refers to numbers that entered follow-up) C2 Serious limitations include lack of proper ascertainment of the TB outcome by smear and/culture, IGRA incorporated in the methods to diagnose TB (South Africa) and lack of adjustment of all confounders. A point is deducted. C3 The results of the studies could be generalized for the specific country/region and for those specific groups of interest. However, the small number of studies warrants caution; a point is deducted for indirectness. C4 The two tests perform comparably and any differences are not statistically significant as the 95% confidence intervals for the pooled IRRs overlap and there is no heterogeneity in the pooled estimates for either test (IGRA+: IRR=3.2, I2=0%, p=0.899 and TST+: IRR=2.3, I2=0%, p=0.383). No points deducted. C5 The confidence intervals of the pooled IRRs are wide (precision > +/- 20%). This is a very serious limitation. Two points are deducted. C6 Publication bias was not formally assessed, but is deemed likely. See B6. E1 Only the Zambian study examined if there was an exposure-gradient relationship between baseline quantitative IGRA levels and subsequent rates of TB in those levels. (N refers to numbers included in this stratified analysis) E2 Lack of proper ascertainment of the TB outcome by smear/culture for both studies. The Zambian study is unpublished and only an interim report was available, so quality could not be fully assessed. A point is deducted. E3 There is only one study. There is serious indirectness. A point is deducted. E4 There is only one study; inconsistency cannot be assessed. A point is deducted. E5 The 95% confidence intervals per IGRA stratum were extremely wide (precision > +/- 20%). Two points are deducted. E6 Publication bias was not formally assessed, but is deemed likely. See B6. F1 The Zambia and South Africa studies further explored rates for TB in paired concordant and discordant TST/IGRA results. (N refers to number included in this stratified analysis) F2 Serious limitations include lack of proper ascertainment of the TB outcome by smear and/culture, IGRA incorporated in the methods to diagnose TB (South Africa) and lack of adjustment of all confounders. A point is deducted F3 Although results may be generalizable to similar L/MIC, there are only two studies. A point is deducted. F4 Rates of TB during follow-up may be higher in those with double positive TST+/IGRA+ results than in those with double negative results. Both studies seem to suggest this. However, contrasting results are seen with regard to discordant pairs. Pooled estimates were not derived. The inconsistency in results is deemed serious; a point is deducted. F5 Observed 95% confidence intervals around the rates per strata are wide (precision > +/- 20%). F6 Publication bias was not formally assessed, but is deemed likely. See B6. G1 All 3 studies were included in this evaluation of patient-relevant outcomes. The diagnostic accuracy estimates of sensitivity and specificity etc are surrogates of patient-relevant outcomes important for assessing the frequency and impact of either a false negative or false positive IGRA result at baseline. A falsely positive outcome may result in possible isoniazid preventive therapy (IPT) prescription for a period of 6-9months, depending on country guidelines. IPT, although safe, is not without serious adverse effects, notably, clinical hepatitis and the increased possibility of drug resistance in the future. Whilst a falsely negative result may result in no IPT being provided and the individual exposed to at least a 2-fold risk of developing TB in the future. G2 Serious limitations include lack of proper ascertainment of the TB outcome by smear and/culture, IGRA incorporated in the methods to diagnose TB and lack of adjustment of all confounders for most studies. A point is deducted G3 Although results may be generalizable to similar L/MIC, there are only three studies. A point is deducted. G4 There is heterogeneity in individual studies’ test accuracy estimates (e.g. specificity/false positive rates). A point is deducted. G5 The summary estimates of sensitivity and specificity are moderate and the confidence intervals are wide (precision > +/- 20%). Two points are deducted. G6 Publication bias was not formally assessed, but is deemed likely. See B6. [Batch job pointed to p30 (list of tables); table is on p58, footnotes on pp. 59-60. No footnotes for outcome D/H; footnote marker in row 4 is printed as \"6\" (not B6).]",
      "narratives": {
        "en": "GRADE evidence profile on the predictive value of commercial IGRAs for incident active TB in low- and middle-income countries. Eight outcomes (from efficacy of IGRA-based preventive therapy to the utility of serial IGRA testing) are listed; those with cohort data are rated for design, limitations, indirectness, inconsistency, imprecision, publication bias, quality of evidence and importance.",
        "ar": "ملف بيّنات وفق منهجية GRADE بشأن القيمة التنبؤية لمقايسات إطلاق الإنترفيرون غاما التجارية للإصابة بالسل النشط في البلدان المنخفضة والمتوسطة الدخل. ويسرد ثماني حصائل (من فعالية العلاج الوقائي المستند إلى المقايسات إلى جدوى تكرار الاختبار)، وتُقيَّم الحصائل التي تتوفر بشأنها بيانات أترابية من حيث التصميم والقيود وعدم المباشرة وعدم الاتساق وعدم الدقة وتحيز النشر وجودة البيّنات والأهمية.",
        "zh": "GRADE证据概况表，涉及商品化γ干扰素释放试验对中低收入国家新发活动性结核的预测价值。列出八项结局（从基于IGRA的预防性治疗效果到连续IGRA检测的作用）；有队列数据的结局按设计、局限性、间接性、不一致性、不精确性、发表偏倚、证据质量和重要性评价。",
        "es": "Perfil de evidencia GRADE sobre el valor predictivo de los IGRA comerciales para la tuberculosis activa incidente en países de ingresos bajos y medianos. Se enumeran ocho resultados (desde la eficacia del tratamiento preventivo basado en IGRA hasta la utilidad de las pruebas IGRA seriadas); los que cuentan con datos de cohortes se califican por diseño, limitaciones, carácter indirecto, incoherencia, imprecisión, sesgo de publicación, calidad de la evidencia e importancia.",
        "fr": "Profil de données probantes GRADE sur la valeur prédictive des tests IGRA commerciaux pour la tuberculose active incidente dans les pays à revenu faible ou intermédiaire. Huit critères sont énumérés (de l’efficacité du traitement préventif fondé sur les IGRA à l’utilité des tests IGRA répétés) ; ceux pour lesquels il existe des données de cohorte sont évalués selon le plan, les limites, le caractère indirect, l’incohérence, l’imprécision, le biais de publication, la qualité des données et l’importance.",
        "ru": "Профиль доказательств GRADE о прогностической ценности коммерческих тестов IGRA в отношении новых случаев активного туберкулеза в странах с низким и средним уровнем дохода. Перечислены восемь исходов (от эффективности профилактического лечения по результатам IGRA до пользы повторного тестирования); исходы с когортными данными оцениваются по дизайну, ограничениям, косвенности, несогласованности, неточности, публикационной ошибке, качеству доказательств и значимости."
      },
      "csv": "tables/table-12.csv"
    },
    {
      "label": "Table 13",
      "caption": "Table 13. GRADE Summary of Findings: Predictive value of commercial IGRA for incident active TB in low and middle-income countries",
      "pages": [
        61,
        62,
        63,
        64
      ],
      "columns": [
        {
          "titles": "Outcome"
        },
        {
          "titles": "N (No. of studies)"
        },
        {
          "titles": "Principal Findings"
        },
        {
          "titles": "What do these findings mean?"
        },
        {
          "titles": "Quality of Evidence"
        },
        {
          "titles": "Importance"
        }
      ],
      "rows": [
        [
          "Efficacy of preventive therapy based on IGRA results",
          "No studies",
          "",
          "",
          "",
          "Critical (7-9)"
        ],
        [
          "Prospective predictive value of IGRA for the development of active incident TB? (Do IGRA positive results have a stronger association with subsequent development of active TB compared to IGRA negative results?)",
          "7,392 (3)",
          "1) IGRA positives results appear to have a moderate but higher statistical association with incident TB compared to IGRA negatives, pooled IRR=3.2 (95% CI 0.74-5.64), I2=0%, p=0.91. This estimate is not statistically significant- the confidence interval includes the null. Furthermore, the small number of studies, the heterogeneity of populations studied all warrants caution when interpreting the pooled results. Despite the lack of evidence for statistical heterogeneity. 2) IGRA positives results appear to have higher rates of incident TB than IGRA negatives. A pooled IR (IGRA+)=16.5 (95% CI 11.24-21.7), I2=98%, p<0.0001 and IR (IGRA-)=2.85 (95% CI 0.86-4.84), I2=35%, p=0.217. The 95% CI do not overlap suggesting the difference may be significant. However, this is based on just three studies with different populations. The pooled results should be interpreted with caution; there is low-high statistical heterogeneity.",
          "Moderate increase in incidence rates of TB in IGRA positives compared to IGRA negatives. This translates to moderate risk of progression. There are too few studies to conclude this with certainty. However, even in those with positive IGRA results, the vast majority of individuals did not progress to TB disease during follow-up.",
          "Very low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "Predictive value of IGRA for the development of active incident TB compared to the TST (Do IGRAs (positive vs. negative) have a stronger statistical association with subsequent active TB than the TST (positive vs. negative)?",
          "7,392 (3)",
          "1) IGRA+: Pooled IRR=3.24 (0.62-4.69); I2=0%, p=0.90 2) TST+: Pooled IRR=2.3 (0.83-3.73); I2=0%, p=0.38 The derived estimates are not statistically significant; the confidence intervals include the null. The pooled estimates should also be interpreted cautiously: there are only three studies; heterogeneous populations and study methods",
          "IGRA+ and TST+ may have a similar strength of association with subsequent TB compared to test negative individuals.",
          "Very low ⊕○○○",
          "Critical (7-9)"
        ],
        [
          "Predictive value of IGRA for subsequent TB when IGRA are evaluated as part of a multivariable clinical algorithm for predicting TB (Additive value of IGRA)",
          "No studies",
          "",
          "",
          "",
          "Important (4-6)"
        ],
        [
          "Quantitative IGRA levels and subsequent rates of TB",
          "721 (1)",
          "No pooled estimates: there is only one study It suggests no exposure-gradient relationship between quantitative IGRA levels and rates of subsequent TB. Rates appeared highest in the lowest IGRA quartile, 0.35-0.64 IU/ml at 73.8/1000PY (23.8-228.94), and not at subsequent higher strata, 0.65-3.94 IU/ml at 30.1 (12.5-72.4), 3.95-10 IU/ml at 0 rate per/1000PY and the highest IGRA quartile of >10 IU/ml at 50/1000PY (18.8-133.1). However, comparisons across the strata are not statistically significant, as confidence intervals overlap and results should be interpreted with caution.",
          "Inconclusive results. Number of studies assessed is too small.",
          "Very low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "Immunological phenotypes of discordant-concordant TST/IGRA pairs and subsequent rates of TB",
          "5,861 (2)",
          "No pooled estimates. Rates of TB during follow-up may be higher in those with double positive TST+/IGRA+ results than in those with double negative results. The Zambia study reported higher rates in the discordant pair where IGRA was the positive tests compared to when TST was the positive tests, 29.7/1000PY (13.4 – 66.2) and 0 for IGRA+/TST- and IGRA-/TST+, respectively. By contrast the South African study reported marginally higher rates in IGRA-/TST+ of 3.3/1000PY (0.4-12.0) than in IGRA+/TST- of 1.8/1000PY (0.4-5.4). However, these differences are not significant as the confidence intervals are wide and overlap.",
          "Inconclusive results. Numbers of studies is too small and/or the rate of TB observed per strata too low.",
          "Very low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "Sensitivity, Specificity, False positive rates etc for active TB (as surrogates of patient relevant outcomes)",
          "7,392 (3)",
          "No pooled results. IGRA sensitivity for incident TB was 88% (64-99), 75% (48-93) and 75% (61-86) for the China (T-SPOT.TB), Zambia (QFT-GIT) and South Africa (QFT-GIT) studies, respectively. Specificity was low across the studies at 35% (30-41), 50% (46-54) and 49% (48-51). That means, the false positive rate (100-specificity) for the studies will be 65% (59-70), 50% (46-54) and 51% (49-52). Based on a positive IGRA alone, all these individuals would unnecessarily receive IPT. TST sensitivity for incident TB was similar at 76% (50-93) and 73% (59-84) for the China and South Africa studies, respectively. Specificity for those studies was 35% (29-41) and 58% (57-58). The proportions that would unnecessarily receive IPT based on IPT alone would be 65% (59-71) and 42% (41-42) for the China and South Africa studies, respectively. By contrast sensitivity for subsequent TB disease was poorest for the Zambia study at 44% (20-70) with a specificity of 67% (64-71). The Zambia study acknowledged logistical issues at the clinical sites that possibly affected TST results.",
          "IGRA have moderate sensitivity for subsequent TB in keeping with observed moderate rates. This is not different from the TST. False positive rate is similar for both tests. The proportions scored positive by IGRA and TST are similar for the China and South Africa studies. By contrast, the proportion IGRA+ is higher than TST+ for the Zambia study. However, lower TST results may have resulted from logistical issues.",
          "Very low ⊕○○○",
          "Important (4-6)"
        ],
        [
          "Utility of repeated or serial IGRA results for predicting subsequent incident active TB",
          "No studies",
          "",
          "",
          "",
          "Important (4-6)"
        ]
      ],
      "notes": "Header block above the table: Review question: What is the predictive value of interferon-gamma release assays for incident active tuberculosis disease in low and middle-income countries? Patients/population: Studies of adults or children without TB at baseline and regardless of HIV infection status. Setting: Community-based cohort in a high-burden country, high-risk for TB individuals attending outpatients clinics and school-going adolescents residing in a high-burden country. Index test: Latest Commercial IGRA (QuantiFERON Gold In Tube and T-SPOT.TB). Importance: The predictive value of IGRAs for subsequent incident TB is uncertain. Longitudinal studies on the predictive (prognostic) value of a positive IGRA are emerging. Data from these studies provide the initial evidence to refute or support the use of IGRAs in targeting chemoprophylaxis for IGRA-positive individuals. Reference standard: Development of TB. See hierarchy of reference standards. Studies: Any longitudinal study design (e.g. prospective or retrospective cohort), low and middle-income countries. Follow-up (of any length) should be described. This can either be active or passive follow-up. [Batch job pointed to p30 (list of tables); table runs pp. 61-64 (p64 rendered separately).]",
      "narratives": {
        "en": "GRADE summary of findings on the predictive value of commercial IGRAs for incident active TB in low- and middle-income countries. Rows are eight outcomes (including predictive value versus IGRA-negative and versus TST, quantitative IGRA levels, discordant TST/IGRA pairs and test accuracy for incident TB); columns give participants and studies, principal findings, what they mean, quality of evidence and importance.",
        "ar": "ملخص نتائج وفق منهجية GRADE بشأن القيمة التنبؤية لمقايسات إطلاق الإنترفيرون غاما التجارية للإصابة بالسل النشط في البلدان المنخفضة والمتوسطة الدخل. تمثل الصفوف ثماني حصائل (منها القيمة التنبؤية مقارنة بالنتائج السلبية وباختبار التوبركولين الجلدي، والمستويات الكمية للمقايسات، والأزواج المتعارضة من النتائج، ودقة الاختبار)، وتعرض الأعمدة عدد المشاركين والدراسات والنتائج الرئيسية ومدلولها وجودة البيّنات والأهمية.",
        "zh": "GRADE结果摘要表，涉及商品化γ干扰素释放试验对中低收入国家新发活动性结核的预测价值。各行为八项结局（包括与IGRA阴性及与结核菌素皮肤试验相比的预测价值、IGRA定量水平、TST/IGRA不一致结果对以及对新发结核的检测准确性）；各列为参与者和研究数、主要结果、其含义、证据质量和重要性。",
        "es": "Resumen de resultados GRADE sobre el valor predictivo de los IGRA comerciales para la tuberculosis activa incidente en países de ingresos bajos y medianos. Las filas son ocho resultados (entre ellos el valor predictivo frente a resultados negativos y frente a la PCT, los niveles cuantitativos de IGRA, los pares PCT/IGRA discordantes y la exactitud para la tuberculosis incidente); las columnas indican participantes y estudios, hallazgos principales, su significado, calidad de la evidencia e importancia.",
        "fr": "Synthèse des résultats GRADE sur la valeur prédictive des tests IGRA commerciaux pour la tuberculose active incidente dans les pays à revenu faible ou intermédiaire. Les lignes sont huit critères (dont la valeur prédictive par rapport aux résultats négatifs et à l’IDR, les niveaux quantitatifs d’IGRA, les paires IDR/IGRA discordantes et l’exactitude pour la tuberculose incidente) ; les colonnes donnent participants et études, principaux résultats, leur signification, la qualité des données et l’importance.",
        "ru": "Сводка результатов GRADE о прогностической ценности коммерческих тестов IGRA в отношении новых случаев активного туберкулеза в странах с низким и средним уровнем дохода. Строки — восемь исходов (в том числе прогностическая ценность по сравнению с отрицательными результатами и с ТКП, количественные уровни IGRA, несогласующиеся пары ТКП/IGRA и точность в отношении новых случаев); столбцы — число участников и исследований, основные результаты, их значение, качество доказательств и значимость."
      },
      "csv": "tables/table-13.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 42,
      "note": "inferred"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 43,
      "note": "3 levels"
    },
    {
      "kind": "figures",
      "state": "none"
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 13
    },
    {
      "kind": "references",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "glossary",
      "state": "none",
      "note": "no such heading in the text"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "found",
      "count": 43,
      "note": "43 of 43 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-44759"
  }
}
